BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Younossi ZM. Non-alcoholic fatty liver disease – A global public health perspective. Journal of Hepatology 2019;70:531-44. [DOI: 10.1016/j.jhep.2018.10.033] [Cited by in Crossref: 452] [Cited by in F6Publishing: 433] [Article Influence: 150.7] [Reference Citation Analysis]
Number Citing Articles
1 Wen X, Zhou X, Chen D, Cheng J, Ji L. Association between non-alcoholic fatty liver disease and diabetes-related microvascular complications: A retrospective cross-sectional study of hospitalized patients. Endocr Pract 2021:S1530-891X(21)00046-X. [PMID: 33601024 DOI: 10.1016/j.eprac.2021.02.004] [Reference Citation Analysis]
2 Kořínek R, Pfleger L, Eckstein K, Beiglböck H, Robinson SD, Krebs M, Trattnig S, Starčuk Z Jr, Krššák M. Feasibility of Hepatic Fat Quantification Using Proton Density Fat Fraction by Multi-Echo Chemical-Shift-Encoded MRI at 7T. Front Phys 2021;9:665562. [PMID: 34849373 DOI: 10.3389/fphy.2021.665562] [Reference Citation Analysis]
3 Yang SS, Chen YH, Hu JT, Chiu CF, Hung SW, Chang YC, Chiu CC, Chuang HL. Aldehyde Dehydrogenase Mutation Exacerbated High-Fat-Diet-Induced Nonalcoholic Fatty Liver Disease with Gut Microbiota Remodeling in Male Mice. Biology (Basel) 2021;10:737. [PMID: 34439969 DOI: 10.3390/biology10080737] [Reference Citation Analysis]
4 Kawaguchi T, Tsutsumi T, Nakano D, Torimura T. MAFLD: Renovation of clinical practice and disease awareness of fatty liver. Hepatol Res 2021. [PMID: 34472683 DOI: 10.1111/hepr.13706] [Reference Citation Analysis]
5 Wu C, Zhou Y, Wang M, Dai G, Liu X, Lai L, Tang S. Bioinformatics Analysis Explores Potential Hub Genes in Nonalcoholic Fatty Liver Disease. Front Genet 2021;12:772487. [PMID: 34777484 DOI: 10.3389/fgene.2021.772487] [Reference Citation Analysis]
6 Li M, Fan R, Peng X, Huang J, Zou H, Yu X, Yang Y, Shi X, Ma D. Association of ANGPTL8 and Resistin With Diabetic Nephropathy in Type 2 Diabetes Mellitus. Front Endocrinol (Lausanne) 2021;12:695750. [PMID: 34603198 DOI: 10.3389/fendo.2021.695750] [Reference Citation Analysis]
7 Yilmaz Y, Byrne CD, Musso G. A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD. Expert Rev Gastroenterol Hepatol 2021;15:345-52. [PMID: 33270482 DOI: 10.1080/17474124.2021.1860019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
8 Won SM, Seo MJ, Kwon MJ, Park KW, Yoon JH. Oral Administration of Latilactobacillus sakei ADM14 Improves Lipid Metabolism and Fecal Microbiota Profile Associated With Metabolic Dysfunction in a High-Fat Diet Mouse Model. Front Microbiol 2021;12:746601. [PMID: 34690997 DOI: 10.3389/fmicb.2021.746601] [Reference Citation Analysis]
9 Ma SY, Sun KS, Zhang M, Zhou X, Zheng XH, Tian SY, Liu YS, Chen L, Gao X, Ye J, Zhou XM, Wang JB, Han Y. Disruption of Plin5 degradation by CMA causes lipid homeostasis imbalance in NAFLD. Liver Int 2020;40:2427-38. [PMID: 32339374 DOI: 10.1111/liv.14492] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
10 Zelber-Sagi S, Ivancovsky-Wajcman D, Fliss-Isakov N, Hahn M, Webb M, Shibolet O, Kariv R, Tirosh O. Serum Malondialdehyde is Associated with Non-Alcoholic Fatty Liver and Related Liver Damage Differentially in Men and Women. Antioxidants (Basel) 2020;9:E578. [PMID: 32630732 DOI: 10.3390/antiox9070578] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
11 Adori C, Daraio T, Kuiper R, Barde S, Horvathova L, Yoshitake T, Ihnatko R, Valladolid-Acebes I, Vercruysse P, Wellendorf AM, Gramignoli R, Bozoky B, Kehr J, Theodorsson E, Cancelas JA, Mravec B, Jorns C, Ellis E, Mulder J, Uhlén M, Bark C, Hökfelt T. Disorganization and degeneration of liver sympathetic innervations in nonalcoholic fatty liver disease revealed by 3D imaging. Sci Adv 2021;7:eabg5733. [PMID: 34290096 DOI: 10.1126/sciadv.abg5733] [Reference Citation Analysis]
12 de Conti A, Tryndyak V, Willett RA, Borowa-Mazgaj B, Watson A, Patton R, Khare S, Muskhelishvili L, Olson GR, Avigan MI, Cerniglia CE, Ross SA, Sanyal AJ, Beland FA, Rusyn I, Pogribny IP. Characterization of the variability in the extent of nonalcoholic fatty liver induced by a high-fat diet in the genetically diverse Collaborative Cross mouse model. FASEB J 2020;34:7773-85. [PMID: 32304142 DOI: 10.1096/fj.202000194R] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Lang A, Kuss O, Filla T, Schlesinger S. Association between per capita sugar consumption and diabetes prevalence mediated by the body mass index: results of a global mediation analysis. Eur J Nutr 2021;60:2121-9. [PMID: 33037438 DOI: 10.1007/s00394-020-02401-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Gonzalez-Cantero A, Teklu M, Sorokin AV, Prussick R, González-Cantero J, Martin-Rodriguez JL, Patel N, Parel PM, Manyak GA, Teague HL, Rodante JA, Keel A, Pérez-Hortet C, Sanchéz-Moya AI, Jiménez N, Ballester A, Solis J, Fernandez-Friera L, Barderas MG, Gonzalez-Calvin JL, Jaen P, Playford MP, Dey AK, Gelfand JM, Mehta NN. Subclinical Liver Disease is Associated with Subclinical Atherosclerosis in Psoriasis: Results from Two Observational Studies. J Invest Dermatol 2021:S0022-202X(21)01461-5. [PMID: 34293354 DOI: 10.1016/j.jid.2021.05.034] [Reference Citation Analysis]
15 Xu F, Wang J, Wang P, Hou T, Zhou H, Zhao Y, Wang J, Liu Y, Liang X. Ursodesoxycholic acid is an FFA4 agonist and reduces hepatic steatosis via FFA4 signaling. Eur J Pharmacol 2022;:174760. [PMID: 35033554 DOI: 10.1016/j.ejphar.2022.174760] [Reference Citation Analysis]
16 Li F, Liu G, Xue P, Ren Z, Dai P, Niu W, Xin M. YiQi YangYin Decoction Attenuates Nonalcoholic Fatty Liver Disease in Type 2 Diabetes Rats. Evid Based Complement Alternat Med 2021;2021:5511019. [PMID: 34621322 DOI: 10.1155/2021/5511019] [Reference Citation Analysis]
17 Zhang Y, Zhou X, Liu P, Chen X, Zhang J, Zhang H, Li S, Chen Y, Song X, Wang J, Zeng H, Zhang X, Tang C, Yu C, Li Y, Xu C. GCSF deficiency attenuates nonalcoholic fatty liver disease through regulating GCSFR-SOCS3-JAK-STAT3 pathway and immune cells infiltration. Am J Physiol Gastrointest Liver Physiol 2021;320:G531-42. [PMID: 33470903 DOI: 10.1152/ajpgi.00342.2020] [Reference Citation Analysis]
18 Wang J, Ye C, Fei S. Association between APOC3 polymorphisms and non-alcoholic fatty liver disease risk: a meta-analysis. Afr Health Sci 2020;20:1800-8. [PMID: 34394242 DOI: 10.4314/ahs.v20i4.34] [Reference Citation Analysis]
19 Sundaram V, Jalan R, Shah P, Singal AK, Patel AA, Wu T, Noureddin M, Mahmud N, Wong RJ. Acute on Chronic Liver Failure From Nonalcoholic Fatty Liver Disease: A Growing and Aging Cohort With Rising Mortality. Hepatology 2021;73:1932-44. [DOI: 10.1002/hep.31566] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
20 Asai A, Yokohama K, Ohama H, Tsuchimoto Y, Fukunishi S, Higuchi K. Association between Administration of Antithrombotics and Intraperitoneal Hemorrhage in Patients Undergoing Percutaneous Interventions for Liver Diseases. J Clin Med 2021;10:2527. [PMID: 34200283 DOI: 10.3390/jcm10112527] [Reference Citation Analysis]
21 Mantovani A, Csermely A, Petracca G, Beatrice G, Corey KE, Simon TG, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2021;6:903-13. [PMID: 34555346 DOI: 10.1016/S2468-1253(21)00308-3] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Alqahtani SA, Paik JM, Biswas R, Arshad T, Henry L, Younossi ZM. Poor Awareness of Liver Disease Among Adults With NAFLD in the United States. Hepatol Commun. [DOI: 10.1002/hep4.1765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Gerges SH, Wahdan SA, Elsherbiny DA, El-Demerdash E. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. Life Sci 2021;271:119220. [PMID: 33592199 DOI: 10.1016/j.lfs.2021.119220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
24 Kim YJ, Park SY, Lee JH. Berteroin ameliorates lipid accumulation through AMPK-mediated regulation of hepatic lipid metabolism and inhibition of adipocyte differentiation. Life Sci 2021;282:119668. [PMID: 34087283 DOI: 10.1016/j.lfs.2021.119668] [Reference Citation Analysis]
25 Eshraghian A, Nikeghbalian S, Kazemi K, Shamsaeefar A, Geramizadeh B, Malek-Hosseini SA. Non-alcoholic fatty liver disease after liver transplantation in patients with non-alcoholic steatohepatitis and cryptogenic cirrhosis: the impact of pre-transplant graft steatosis. HPB (Oxford) 2020;22:521-8. [PMID: 31431413 DOI: 10.1016/j.hpb.2019.07.015] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 An YA, Chen S, Deng Y, Wang ZV, Funcke JB, Shah M, Shan B, Gordillo R, Yoshino J, Klein S, Kusminski CM, Scherer PE. The mitochondrial dicarboxylate carrier prevents hepatic lipotoxicity by inhibiting white adipocyte lipolysis. J Hepatol 2021;75:387-99. [PMID: 33746082 DOI: 10.1016/j.jhep.2021.03.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
27 Feng D, Zhang H, Jiang X, Zou J, Li Q, Mai H, Su D, Ling W, Feng X. Bisphenol A exposure induces gut microbiota dysbiosis and consequent activation of gut-liver axis leading to hepatic steatosis in CD-1 mice. Environ Pollut 2020;265:114880. [PMID: 32540565 DOI: 10.1016/j.envpol.2020.114880] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
28 Juanola O, Martínez-López S, Francés R, Gómez-Hurtado I. Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors. Int J Environ Res Public Health 2021;18:5227. [PMID: 34069012 DOI: 10.3390/ijerph18105227] [Reference Citation Analysis]
29 Carr RM. VCAM-1: closing the gap between lipotoxicity and endothelial dysfunction in nonalcoholic steatohepatitis. J Clin Invest 2021;131:147556. [PMID: 33720049 DOI: 10.1172/JCI147556] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
30 Xia B, Peng J, Enrico T, Lu K, Cheung EC, Kuo Z, He Q, Tang Y, Liu A, Fan D, Zhang C, He Y, Pan Y, Yuan J. Metabolic syndrome and its component traits present gender-specific association with liver cancer risk: a prospective cohort study. BMC Cancer 2021;21:1084. [PMID: 34620113 DOI: 10.1186/s12885-021-08760-1] [Reference Citation Analysis]
31 Hu C, Zhang Y, Wang S, Lin L, Peng K, Du R, Qi H, Zhang J, Wang T, Zhao Z, Li M, Xu Y, Xu M, Li D, Bi Y, Wang W, Chen Y, Lu J. Association of bedtime with the risk of non‐alcoholic fatty liver disease among middle‐aged and elderly Chinese adults with pre‐diabetes and diabetes. Diabetes Metab Res Rev 2020;36. [DOI: 10.1002/dmrr.3322] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Ma C, Liu Y, He S, Zeng J, Li P, Ma C, Ping F, Zhang H, Xu L, Li W, Li Y. Negative association between antioxidant vitamin intake and non-alcoholic fatty liver disease in Chinese non-diabetic adults: mediation models involving superoxide dismutase. Free Radic Res 2020;54:670-7. [PMID: 32985285 DOI: 10.1080/10715762.2020.1825705] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Higuera-de-la-Tijera F, Córdova-Gallardo J, Buganza-Torio E, Barranco-Fragoso B, Torre A, Parraguirre-Martínez S, Rojano-Rodríguez ME, Quintero-Bustos G, Castro-Narro G, Moctezuma-Velazquez C. Hepamet Fibrosis Score in Nonalcoholic Fatty Liver Disease Patients in Mexico: Lower than Expected Positive Predictive Value. Dig Dis Sci 2021. [PMID: 33428035 DOI: 10.1007/s10620-020-06821-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Kim HY, Kwon WY, Park JB, Lee MH, Oh YJ, Suh S, Baek YH, Jeong JS, Yoo YH. Hepatic STAMP2 mediates recombinant FGF21-induced improvement of hepatic iron overload in nonalcoholic fatty liver disease. FASEB J 2020;34:12354-66. [PMID: 32721044 DOI: 10.1096/fj.202000790R] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Hsiao CC, Teng PH, Wu YJ, Shen YW, Mar GY, Wu FZ. Severe, but not mild to moderate, non-alcoholic fatty liver disease associated with increased risk of subclinical coronary atherosclerosis. BMC Cardiovasc Disord 2021;21:244. [PMID: 34011282 DOI: 10.1186/s12872-021-02060-z] [Reference Citation Analysis]
36 Chen LJ, Lin XX, Guo J, Xu Y, Zhang SX, Chen D, Zhao Q, Xiao J, Lian GH, Peng SF, Guo D, Yang H, Shu Y, Zhou HH, Zhang W, Chen Y. Lrp6 Genotype affects Individual Susceptibility to Nonalcoholic Fatty Liver Disease and Silibinin Therapeutic Response via Wnt/β-catenin-Cyp2e1 Signaling. Int J Biol Sci 2021;17:3936-53. [PMID: 34671210 DOI: 10.7150/ijbs.63732] [Reference Citation Analysis]
37 Rahmadi M, Nurhan AD, Pratiwi ED, Prameswari DA, Panggono SM, Nisak K, Khotib J. The effect of various high-fat diet on liver histology in the development of NAFLD models in mice. J Basic Clin Physiol Pharmacol 2021;32:547-53. [PMID: 34214382 DOI: 10.1515/jbcpp-2020-0426] [Reference Citation Analysis]
38 Hasan F, Daher HB. The Burden and Clinical Care Pathways of Nonalcoholic Steatohepatitis in the Middle East. Clin Liver Dis (Hoboken) 2019;14:207-11. [PMID: 32015870 DOI: 10.1002/cld.885] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Lonardo A, Leoni S, Alswat KA, Fouad Y. History of Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2020;21:E5888. [PMID: 32824337 DOI: 10.3390/ijms21165888] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
40 Xia Y, Zhao Z, Zhang S, Liu Y, Meng G, Zhang Q, Liu L, Wu H, Gu Y, Wang Y, Zhang T, Wang X, Sun S, Zhou M, Jia Q, Song K, Wu Q, Niu K, Zhao Y. Complex Dietary Topologies in Non-alcoholic Fatty Liver Disease: A Network Science Analysis. Front Nutr 2020;7:579086. [PMID: 33117844 DOI: 10.3389/fnut.2020.579086] [Reference Citation Analysis]
41 Bianco C, Tavaglione F, Romeo S, Valenti L. Genetic risk scores and personalization of care in fatty liver disease. Curr Opin Pharmacol 2021;61:6-11. [PMID: 34537584 DOI: 10.1016/j.coph.2021.08.014] [Reference Citation Analysis]
42 Li B, Hong Y, Gu Y, Ye S, Hu K, Yao J, Ding K, Zhao A, Jia W, Li H. Functional Metabolomics Reveals that Astragalus Polysaccharides Improve Lipids Metabolism through Microbial Metabolite 2-Hydroxybutyric Acid in Obese Mice. Engineering 2020. [DOI: 10.1016/j.eng.2020.05.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Majumdar A, Tsochatzis EA. Changing trends of liver transplantation and mortality from non-alcoholic fatty liver disease. Metabolism 2020;111:154291. [DOI: 10.1016/j.metabol.2020.154291] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
44 Cadamuro M, Lasagni A, Sarcognato S, Guido M, Fabris R, Strazzabosco M, Strain AJ, Simioni P, Villa E, Fabris L. The Neglected Role of Bile Duct Epithelial Cells in NASH. Semin Liver Dis 2021. [PMID: 34794182 DOI: 10.1055/s-0041-1739455] [Reference Citation Analysis]
45 Sarin SK, Prasad M, Ramalingam A, Kapil U. Integration of public health measures for NAFLD into India's national programme for NCDs. Lancet Gastroenterol Hepatol 2021;6:777-8. [PMID: 34509189 DOI: 10.1016/S2468-1253(21)00264-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Tutunchi H, Naeini F, Ebrahimi-Mameghani M, Mobasseri M, Naghshi S, Ostadrahimi A. The association of the steatosis severity, NAFLD fibrosis score and FIB-4 index with atherogenic dyslipidaemia in adult patients with NAFLD: A cross-sectional study. Int J Clin Pract 2021;75:e14131. [PMID: 33683797 DOI: 10.1111/ijcp.14131] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
47 Zhou YJ, Zheng KI, Wang XB, Yan HD, Sun QF, Pan KH, Wang TY, Ma HL, Chen YP, George J, Zheng MH. Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis. J Hepatol. 2020;73:719-721. [PMID: 32348790 DOI: 10.1016/j.jhep.2020.04.027] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 25.5] [Reference Citation Analysis]
48 Takakura K, Oikawa T, Nakano M, Saeki C, Torisu Y, Kajihara M, Saruta M. Recent Insights Into the Multiple Pathways Driving Non-alcoholic Steatohepatitis-Derived Hepatocellular Carcinoma.Front Oncol. 2019;9:762. [PMID: 31456946 DOI: 10.3389/fonc.2019.00762] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
49 Olubamwo OO, Virtanen JK, Pihlajamaki J, Mantyselka P, Tuomainen TP. Fatty liver index as a predictor of increased risk of cardiometabolic disease: finding from the Kuopio Ischaemic Heart Disease Risk Factor Study Cohort. BMJ Open 2019;9:e031420. [PMID: 31492793 DOI: 10.1136/bmjopen-2019-031420] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
50 Kubihal S, Gupta Y, Shalimar, Kandasamy D, Goyal A, Kalaivani M, Goyal A, Kedia S, Kachhawa G, Ambekar S, Bhatia D, Garg V, Gupta N, Tandon N. Prevalence of non-alcoholic fatty liver disease and factors associated with it in Indian women with a history of gestational diabetes mellitus. J Diabetes Investig 2021;12:877-85. [PMID: 32961610 DOI: 10.1111/jdi.13411] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
51 Chang TY, Chang SH, Lin YH, Ho WC, Wang CY, Jeng WJ, Wan YL, Tsui PH. Utility of quantitative ultrasound in community screening for hepatic steatosis. Ultrasonics 2021;111:106329. [PMID: 33338730 DOI: 10.1016/j.ultras.2020.106329] [Reference Citation Analysis]
52 Sharma V, Sharma R, Gautam DS, Kuca K, Nepovimova E, Martins N. Role of Vacha (Acorus calamus Linn.) in Neurological and Metabolic Disorders: Evidence from Ethnopharmacology, Phytochemistry, Pharmacology and Clinical Study. J Clin Med 2020;9:E1176. [PMID: 32325895 DOI: 10.3390/jcm9041176] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
53 Yang M, Kimchi ET, Staveley-O'Carroll KF, Li G. Astaxanthin Prevents Diet-Induced NASH Progression by Shaping Intrahepatic Immunity. Int J Mol Sci 2021;22:11037. [PMID: 34681695 DOI: 10.3390/ijms222011037] [Reference Citation Analysis]
54 Hu DS, Zhu SH, Liu WY, Pan XY, Zhu PW, Li YY, Zheng KI, Ma HL, You J, Targher G, Byrne CD, Chen YP, Zheng MH. PNPLA3 polymorphism influences the association between high-normal TSH level and NASH in euthyroid adults with biopsy-proven NAFLD. Diabetes Metab 2020;46:496-503. [PMID: 32035968 DOI: 10.1016/j.diabet.2020.02.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
55 Long MT, Massaro JM, Hoffmann U, Benjamin EJ, Naimi TS. Alcohol Use Is Associated With Hepatic Steatosis Among Persons With Presumed Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2020;18:1831-1841.e5. [PMID: 31734449 DOI: 10.1016/j.cgh.2019.11.022] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
56 Catania R, Furlan A, Smith AD, Behari J, Tublin ME, Borhani AA. Diagnostic value of MRI-derived liver surface nodularity score for the non-invasive quantification of hepatic fibrosis in non-alcoholic fatty liver disease. Eur Radiol 2021;31:256-63. [PMID: 32757050 DOI: 10.1007/s00330-020-07114-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
57 Yoo ER, Kim D, Vazquez‐montesino LM, Escober JA, Li AA, Tighe SP, Fernandes CT, Cholankeril G, Ahmed A. Diet quality and its association with nonalcoholic fatty liver disease and all‐cause and cause‐specific mortality. Liver Int 2020;40:815-24. [DOI: 10.1111/liv.14374] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
58 Raselli T, Hearn T, Wyss A, Atrott K, Peter A, Frey-Wagner I, Spalinger MR, Maggio EM, Sailer AW, Schmitt J, Schreiner P, Moncsek A, Mertens J, Scharl M, Griffiths WJ, Bueter M, Geier A, Rogler G, Wang Y, Misselwitz B. Elevated oxysterol levels in human and mouse livers reflect nonalcoholic steatohepatitis. J Lipid Res 2019;60:1270-83. [PMID: 31113816 DOI: 10.1194/jlr.M093229] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 5.3] [Reference Citation Analysis]
59 Zhang S, Wu X, Bian S, Zhang Q, Liu L, Meng G, Yao Z, Wu H, Gu Y, Wang Y, Sun S, Wang X, Zhou M, Jia Q, Song K, Niu K. Association between consumption frequency of honey and non-alcoholic fatty liver disease: results from a cross-sectional analysis based on the Tianjin Chronic Low-grade Systemic Inflammation and Health (TCLSIH) Cohort Study. Br J Nutr 2021;125:712-20. [PMID: 32799936 DOI: 10.1017/S0007114520003190] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
60 Zhang Z, Zong C, Jiang M, Hu H, Cheng X, Ni J, Yi X, Jiang B, Tian F, Chang MW, Su W, Zhu L, Li J, Xiang X, Miao C, Gorospe M, de Cabo R, Dou Y, Ju Z, Yang J, Jiang C, Yang Z, Wang W. Hepatic HuR modulates lipid homeostasis in response to high-fat diet. Nat Commun 2020;11:3067. [PMID: 32546794 DOI: 10.1038/s41467-020-16918-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
61 Alvarez CS, Florio AA, Butt J, Rivera-Andrade A, Kroker-Lobos MF, Waterboer T, Camargo MC, Freedman ND, Graubard BI, Lazo M, Guallar E, Groopman JD, Ramírez-Zea M, McGlynn KA. Associations between Helicobacter pylori with nonalcoholic fatty liver disease and other metabolic conditions in Guatemala. Helicobacter 2020;25:e12756. [PMID: 33006810 DOI: 10.1111/hel.12756] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 Zhang S, Gan S, Zhang Q, Liu L, Meng G, Yao Z, Wu H, Gu Y, Wang Y, Zhang T, Wang X, Sun S, Wang X, Zhou M, Jia Q, Song K, Qi L, Niu K. Ultra-processed food consumption and the risk of non-alcoholic fatty liver disease in the Tianjin Chronic Low-grade Systemic Inflammation and Health Cohort Study. Int J Epidemiol 2021:dyab174. [PMID: 34528679 DOI: 10.1093/ije/dyab174] [Reference Citation Analysis]
63 Bullón-Vela V, Abete I, Tur JA, Konieczna J, Romaguera D, Pintó X, Corbella E, Martínez-González MA, Sayón-Orea C, Toledo E, Corella D, Macías-Gonzalez M, Tinahones FJ, Fitó M, Estruch R, Ros E, Salas-Salvadó J, Daimiel L, Mascaró CM, Zulet MA, Martínez JA. Relationship of visceral adipose tissue with surrogate insulin resistance and liver markers in individuals with metabolic syndrome chronic complications. Ther Adv Endocrinol Metab 2020;11:2042018820958298. [PMID: 33149882 DOI: 10.1177/2042018820958298] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
64 Mari A, Khoury T, Said Ahmad H, Abu Baker F, Kadah A, Sbeit W, Pellicano R, Mahamid M. The association between non-alcoholic fatty liver disease and valvular heart disease. Minerva Cardioangiol 2020;68:42-6. [PMID: 31789009 DOI: 10.23736/S0026-4725.19.05087-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Hadefi A, Arvanitakis M, Huberty V, Devière J. Metabolic endoscopy: Today's science-tomorrow's treatment. United European Gastroenterol J 2020;8:685-94. [PMID: 32628898 DOI: 10.1177/2050640620926837] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
66 Itoh M, Ogawa Y, Suganami T. Chronic inflammation as a molecular basis of nonalcoholic steatohepatitis: role of macrophages and fibroblasts in the liver. Nagoya J Med Sci 2020;82:391-7. [PMID: 33132423 DOI: 10.18999/nagjms.82.3.391] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
67 Gutiérrez-Cuevas J, Santos A, Armendariz-Borunda J. Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases. Int J Mol Sci 2021;22:11629. [PMID: 34769060 DOI: 10.3390/ijms222111629] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Darand M, Darabi Z, Yari Z, Hedayati M, Shahrbaf MA, Khoncheh A, Hosseini-Ahangar B, Alavian SM, Hekmatdoost A. The effects of black seed supplementation on cardiovascular risk factors in patients with nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled clinical trial. Phytother Res 2019;33:2369-77. [PMID: 31293021 DOI: 10.1002/ptr.6424] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
69 Yong JN, Lim WH, Ng CH, Tan DJH, Xiao J, Tay PWL, Lin SY, Syn N, Chew N, Nah B, Dan YY, Huang DQ, Tan EXX, Sanyal AJ, Noureddin M, Siddiqui MS, Muthiah MD. Outcomes of Nonalcoholic Steatohepatitis After Liver Transplantation: An Updated Meta-Analysis and Systematic Review. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01226-X. [PMID: 34801743 DOI: 10.1016/j.cgh.2021.11.014] [Reference Citation Analysis]
70 Petrick JL, Florio AA, Loomba R, McGlynn KA. Have incidence rates of liver cancer peaked in the United States? Cancer 2020;126:3151-5. [PMID: 32294255 DOI: 10.1002/cncr.32794] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
71 Xia M, Ma S, Huang Q, Zeng H, Ge J, Xu W, Wu Q, Wu L, Li X, Ma H, Chen L, Li Q, Aleteng Q, Hu Y, He W, Pan B, Lin H, Zheng Y, Wang S, Tang H, Gao X. NAFLD-related gene polymorphisms and all-cause and cause-specific mortality in an Asian population: the Shanghai Changfeng Study. Aliment Pharmacol Ther 2022. [PMID: 35023183 DOI: 10.1111/apt.16772] [Reference Citation Analysis]
72 Wu WK, Chen YH, Lee PC, Yang PJ, Chang CC, Liu KL, Hsu CC, Huang CC, Chuang HL, Sheen LY, Liu CJ, Wu MS. Mining Gut Microbiota From Bariatric Surgery for MAFLD. Front Endocrinol (Lausanne) 2021;12:612946. [PMID: 33897617 DOI: 10.3389/fendo.2021.612946] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Chandrasekharan K, Alazawi W. Genetics of Non-Alcoholic Fatty Liver and Cardiovascular Disease: Implications for Therapy? Front Pharmacol 2019;10:1413. [PMID: 31969816 DOI: 10.3389/fphar.2019.01413] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
74 Zambon Azevedo V, Silaghi CA, Maurel T, Silaghi H, Ratziu V, Pais R. Impact of Sarcopenia on the Severity of the Liver Damage in Patients With Non-alcoholic Fatty Liver Disease. Front Nutr 2022;8:774030. [DOI: 10.3389/fnut.2021.774030] [Reference Citation Analysis]
75 Galsgaard KD. The Vicious Circle of Hepatic Glucagon Resistance in Non-Alcoholic Fatty Liver Disease. J Clin Med 2020;9:E4049. [PMID: 33333850 DOI: 10.3390/jcm9124049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
76 Foerster F, Gairing SJ, Müller L, Galle PR. NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. J Hepatol 2021:S0168-8278(21)02037-7. [PMID: 34555422 DOI: 10.1016/j.jhep.2021.09.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Dash S, Aydin Y, Moroz K. Chaperone-Mediated Autophagy in the Liver: Good or Bad? Cells 2019;8:E1308. [PMID: 31652893 DOI: 10.3390/cells8111308] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
78 Berná G, Romero‐gomez M. The role of nutrition in non‐alcoholic fatty liver disease: Pathophysiology and management. Liver Int 2020;40:102-8. [DOI: 10.1111/liv.14360] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 13.5] [Reference Citation Analysis]
79 Zhou J, Long Y, Ding N, Su Y. Association between bedtime at night and nonalcoholic fatty liver disease diagnosed by liver ultrasound transient elastography. Diabetes Research and Clinical Practice 2022. [DOI: 10.1016/j.diabres.2022.109195] [Reference Citation Analysis]
80 Chalasani NP, Porter K, Bhattacharya A, Book AJ, Neis BM, Xiong KM, Ramasubramanian TS, Edwards V DK, Chen I, Johnson S, Roberts LR, Kisiel JB, Reddy KR, Singal AG, Olson MC, Bruinsma JJ. Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00866-1. [PMID: 34391922 DOI: 10.1016/j.cgh.2021.08.010] [Reference Citation Analysis]
81 Ferraioli G, Berzigotti A, Barr RG, Choi BI, Cui XW, Dong Y, Gilja OH, Lee JY, Lee DH, Moriyasu F, Piscaglia F, Sugimoto K, Wong GL, Wong VW, Dietrich CF. Quantification of Liver Fat Content with Ultrasound: A WFUMB Position Paper. Ultrasound Med Biol 2021;47:2803-20. [PMID: 34284932 DOI: 10.1016/j.ultrasmedbio.2021.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
82 Tavaglione F, De Vincentis A, Jamialahmadi O, Pujia R, Spagnuolo R, Picardi A, Morano S, Valenti L, Romeo S, Vespasiani-Gentilucci U. Inborn and acquired risk factors for severe liver disease in Europeans with type 2 diabetes from the UK Biobank. JHEP Rep 2021;3:100262. [PMID: 33997749 DOI: 10.1016/j.jhepr.2021.100262] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Sarkar S, Kimono D, Albadrani M, Seth RK, Busbee P, Alghetaa H, Porter DE, Scott GI, Brooks B, Nagarkatti M, Nagarkatti P, Chatterjee S. Environmental microcystin targets the microbiome and increases the risk of intestinal inflammatory pathology via NOX2 in underlying murine model of Nonalcoholic Fatty Liver Disease. Sci Rep 2019;9:8742. [PMID: 31217465 DOI: 10.1038/s41598-019-45009-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
84 Wang F, Zhang X, Liu W, Zhou Y, Wei W, Liu D, Wong CC, Sung JJY, Yu J. Activated Natural Killer Cell Promotes Nonalcoholic Steatohepatitis Through Mediating JAK/STAT Pathway. Cell Mol Gastroenterol Hepatol 2021:S2352-345X(21)00186-7. [PMID: 34506952 DOI: 10.1016/j.jcmgh.2021.08.019] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Hu MJ, Long M, Dai RJ. Acetylation of H3K27 activated lncRNA NEAT1 and promoted hepatic lipid accumulation in non-alcoholic fatty liver disease via regulating miR-212-5p/GRIA3. Mol Cell Biochem 2021. [PMID: 34652536 DOI: 10.1007/s11010-021-04269-0] [Reference Citation Analysis]
86 Alemany-Pagès M, Moura-Ramos M, Araújo S, Macedo MP, Ribeiro RT, do Ó D, Ramalho-Santos J, Azul AM. Insights from qualitative research on NAFLD awareness with a cohort of T2DM patients: time to go public with insulin resistance? BMC Public Health 2020;20:1142. [PMID: 32690054 DOI: 10.1186/s12889-020-09249-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
87 Chikada H, Ida K, Nishikawa Y, Inagaki Y, Kamiya A. Liver-specific knockout of B cell lymphoma 6 suppresses progression of non-alcoholic steatohepatitis in mice. Sci Rep 2020;10:9704. [PMID: 32546802 DOI: 10.1038/s41598-020-66539-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
88 Bellanti F, Vendemiale G. Coronavirus disease 2019 and non-alcoholic fatty liver disease. World J Hepatol 2021; 13(9): 969-978 [PMID: 34630869 DOI: 10.4254/wjh.v13.i9.969] [Reference Citation Analysis]
89 Xue J, Xin H, Ren N, Zhou C, Yang J, Song L, Qin S. Nonalcoholic fatty liver disease increases the risk of gastroesophageal reflux disease: A systematic review and meta-analysis. Eur J Clin Invest 2019;49:e13158. [PMID: 31338830 DOI: 10.1111/eci.13158] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Zou Y, Zhong L, Hu C, Zhong M, Peng N, Sheng G. LDL/HDL cholesterol ratio is associated with new-onset NAFLD in Chinese non-obese people with normal lipids: a 5-year longitudinal cohort study. Lipids Health Dis 2021;20:28. [PMID: 33766067 DOI: 10.1186/s12944-021-01457-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Zhang W, An R, Li Q, Sun L, Lai X, Chen R, Li D, Sun S. Theaflavin TF3 Relieves Hepatocyte Lipid Deposition through Activating an AMPK Signaling Pathway by targeting Plasma Kallikrein. J Agric Food Chem 2020;68:2673-83. [DOI: 10.1021/acs.jafc.0c00148] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
92 Shockley KR, Cora MC, Malarkey DE, Jackson-Humbles D, Vallant M, Collins BJ, Mutlu E, Robinson VG, Waidyanatha S, Zmarowski A, Machesky N, Richey J, Harbo S, Cheng E, Patton K, Sparrow B, Dunnick JK. Comparative toxicity and liver transcriptomics of legacy and emerging brominated flame retardants following 5-day exposure in the rat. Toxicol Lett 2020;332:222-34. [PMID: 32679240 DOI: 10.1016/j.toxlet.2020.07.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
93 Liu CH, Ampuero J, Pavlides M, Wong VW, Fan JG, Bai L, Li H, Wu DB, Zhou LY, Du LY, Yang TK, Jiang W, Shi Y, Gil-Gómez A, Zhang WT, Liang JX, Romero-Gómez M, Tang H. Simple non-invasive scoring systems and histological scores in predicting mortality in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Gastroenterol Hepatol 2021;36:1754-68. [PMID: 33569851 DOI: 10.1111/jgh.15431] [Reference Citation Analysis]
94 Cai J, Lin C, Lai S, Liu Y, Liang M, Qin Y, Liang X, Tan A, Gao Y, Lu Z, Wu C, Huang S, Yang X, Zhang H, Kuang J, Mo Z. Waist-to-height ratio, an optimal anthropometric indicator for metabolic dysfunction associated fatty liver disease in the Western Chinese male population. Lipids Health Dis 2021;20:145. [PMID: 34706716 DOI: 10.1186/s12944-021-01568-9] [Reference Citation Analysis]
95 Wang C, Ma C, Gong L, Dai S, Li Y. Preventive and therapeutic role of betaine in liver disease: A review on molecular mechanisms. Eur J Pharmacol 2021;912:174604. [PMID: 34743980 DOI: 10.1016/j.ejphar.2021.174604] [Reference Citation Analysis]
96 Shi J, Yang Y, Xu W, Cai H, Wu J, Long J, Cai Q, Zheng W, Flynn CR, Shu XO, Yu D. Sex-Specific Associations between Gut Microbiome and Non-Alcoholic Fatty Liver Disease among Urban Chinese Adults. Microorganisms 2021;9:2118. [PMID: 34683439 DOI: 10.3390/microorganisms9102118] [Reference Citation Analysis]
97 Um YJ, Chang Y, Jung H, Cho IY, Shin JH, Shin H, Wild SH, Byrne CD, Ryu S. Decrease in Sleep Duration and Poor Sleep Quality over Time Is Associated with an Increased Risk of Incident Non-Alcoholic Fatty Liver Disease. JPM 2022;12:92. [DOI: 10.3390/jpm12010092] [Reference Citation Analysis]
98 Tamaki N, Munaganuru N, Jung J, Yonan AQ, Loomba RR, Bettencourt R, Ajmera V, Valasek MA, Behling C, Sirlin CB, Loomba R. Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease. Gut 2021:gutjnl-2021-324264. [PMID: 33883248 DOI: 10.1136/gutjnl-2021-324264] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
99 Mikami K, Endo T, Sawada N, Igarashi G, Kimura M, Hasegawa T, Iino C, Sawada K, Nakaji S, Ishibashi Y, Matsuzaka M, Fukuda S. Association of Bone Metabolism with Fatty Liver Disease in the Elderly in Japan: A Community-based Study. Intern Med 2020;59:1247-56. [PMID: 32101831 DOI: 10.2169/internalmedicine.3906-19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
100 Chatterjee A, Basu A, Das K, Chowdhury A, Basu P. Exome-wide scan identifies significant association of rs4788084 in IL27 promoter with increase in hepatic fat content among Indians. Gene 2021;775:145431. [PMID: 33444683 DOI: 10.1016/j.gene.2021.145431] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Ogawa M, Tsuchiya A, Watanabe T, Setsu T, Kimura N, Matsuda M, Hoshiyama Y, Saito H, Kanazawa T, Shiotani M, Sato T, Yagi T, Igarashi K, Yoshimura N, Takamura M, Aoyama H, Terai S. Screening and follow-up of chronic liver diseases with understanding their etiology in clinics and hospitals. JGH Open 2020;4:827-37. [PMID: 33102751 DOI: 10.1002/jgh3.12406] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
102 Tamargo JA, Sherman KE, Campa A, Martinez SS, Li T, Hernandez J, Teeman C, Mandler RN, Chen J, Ehman RL, Baum MK. Food insecurity is associated with magnetic resonance-determined nonalcoholic fatty liver and liver fibrosis in low-income, middle-aged adults with and without HIV. Am J Clin Nutr 2021;113:593-601. [PMID: 33515016 DOI: 10.1093/ajcn/nqaa362] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
103 Sommerfeld O, von Loeffelholz C, Diab M, Kiessling S, Doenst T, Bauer M, Sponholz C. Association between high dose catecholamine support and liver dysfunction following cardiac surgery. J Card Surg 2020;35:1228-36. [PMID: 32333454 DOI: 10.1111/jocs.14555] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Vahid F, Rahmani D, Hekmatdoost A. The association between dietary antioxidant index (DAI) and nonalcoholic fatty liver disease (NAFLD) onset; new findings from an incident case-control study. Clin Nutr ESPEN 2021;41:360-4. [PMID: 33487290 DOI: 10.1016/j.clnesp.2020.10.020] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
105 Narayanasamy K, Karthick R, Panneerselvam P, Mohan N, Ramachandran A, Prakash R, Rajaram M. Association of metabolic syndrome and patatin-like phospholipase 3 - rs738409 gene variant in non-alcoholic fatty liver disease among a Chennai-based south Indian population. J Gene Med 2020;22:e3160. [PMID: 31945251 DOI: 10.1002/jgm.3160] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
106 Kim D, Vazquez-Montesino LM, Escober JA, Fernandes CT, Cholankeril G, Loomba R, Harrison SA, Younossi ZM, Ahmed A. Low Thyroid Function in Nonalcoholic Fatty Liver Disease Is an Independent Predictor of All-Cause and Cardiovascular Mortality. Am J Gastroenterol 2020;115:1496-504. [PMID: 32496342 DOI: 10.14309/ajg.0000000000000654] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
107 Li J, Liu M, Li Y, Sun DD, Shu Z, Tan Q, Guo S, Xie R, Gao L, Ru H, Zang Y, Liu H, Li J, Zhou Y. Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis. J Med Chem 2020;63:12748-72. [PMID: 32991173 DOI: 10.1021/acs.jmedchem.0c01065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
108 Kasper P, Martin A, Lang S, Kütting F, Goeser T, Demir M, Steffen HM. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol 2021;110:921-37. [PMID: 32696080 DOI: 10.1007/s00392-020-01709-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 11.0] [Reference Citation Analysis]
109 Xia MF, Bian H, Gao X. NAFLD and Diabetes: Two Sides of the Same Coin? Rationale for Gene-Based Personalized NAFLD Treatment. Front Pharmacol. 2019;10:877. [PMID: 31447675 DOI: 10.3389/fphar.2019.00877] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
110 Donato F, Moneda M, Portolani N, Rossini A, Molfino S, Ministrini S, Contessi GB, Pesenti S, De Palma G, Gaia A, Zanardini E, Sileo CV, Magoni M. Polychlorinated biphenyls and risk of hepatocellular carcinoma in the population living in a highly polluted area in Italy. Sci Rep 2021;11:3064. [PMID: 33542320 DOI: 10.1038/s41598-021-82657-8] [Reference Citation Analysis]
111 Zandani G, Anavi-Cohen S, Tsybina-Shimshilashvili N, Sela N, Nyska A, Madar Z. Broccoli Florets Supplementation Improves Insulin Sensitivity and Alters Gut Microbiome Population-A Steatosis Mice Model Induced by High-Fat Diet. Front Nutr 2021;8:680241. [PMID: 34395490 DOI: 10.3389/fnut.2021.680241] [Reference Citation Analysis]
112 Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol 2021;18:599-612. [PMID: 33972770 DOI: 10.1038/s41575-021-00448-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
113 Billeter AT, Müller PC, Albrecht T, Roessler S, Löffler M, Lemekhova A, Mehrabi A, Müller-Stich BP, Hoffmann K. Impact of Type 2 Diabetes on Oncologic Outcomes of Hepatocellular Carcinomas in Non-Cirrhotic, Non-alcoholic Steatohepatitis: a Matched-Pair Analysis. J Gastrointest Surg 2021;25:1193-202. [PMID: 32378092 DOI: 10.1007/s11605-020-04628-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
114 Kutaiba N, Richmond D, Morey M, Brennan D, Rotella JA, Ardalan Z, Goodwin M. Incidental hepatic steatosis on unenhanced computed tomography performed for suspected renal colic: Gaps in reporting and documentation. J Med Imaging Radiat Oncol 2019;63:431-8. [PMID: 30874372 DOI: 10.1111/1754-9485.12873] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
115 Hashida R, Nakano D, Yamamura S, Kawaguchi T, Tsutsumi T, Matsuse H, Takahashi H, Gerber L, Younossi ZM, Torimura T. Association between Activity and Brain-Derived Neurotrophic Factor in Patients with Non-Alcoholic Fatty Liver Disease: A Data-Mining Analysis. Life (Basel) 2021;11:799. [PMID: 34440543 DOI: 10.3390/life11080799] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Kim H, Lee DS, An TH, Park HJ, Kim WK, Bae KH, Oh KJ. Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC. Int J Mol Sci 2021;22:4495. [PMID: 33925827 DOI: 10.3390/ijms22094495] [Reference Citation Analysis]
117 Younossi ZM, Ong JP, Takahashi H, Yilmaz Y, Eguchi Y, El Kassas M, Buti M, Diago M, Zheng MH, Fan JG, Yu ML, Wai-Sun Wong V, Alswat K, Chan WK, Mendez-Sanchez N, Burra P, Bugianesi E, Duseja AK, George J, Papatheodoridis GV, Saeed H, Castera L, Arrese M, Kugelmas M, Romero-Gomez M, Alqahtani S, Ziayee M, Lam B, Younossi I, Racila A, Henry L, Stepanova M; Global NASH Council. A Global Survey of Physicians Knowledge About Non-alcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00719-9. [PMID: 34229038 DOI: 10.1016/j.cgh.2021.06.048] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
118 Thomaides-Brears HB, Alkhouri N, Allende D, Harisinghani M, Noureddin M, Reau NS, French M, Pantoja C, Mouchti S, Cryer DRH. Incidence of Complications from Percutaneous Biopsy in Chronic Liver Disease: A Systematic Review and Meta-Analysis. Dig Dis Sci 2021. [PMID: 34129125 DOI: 10.1007/s10620-021-07089-w] [Reference Citation Analysis]
119 Qian M, Hu H, Yao Y, Zhao D, Wang S, Pan C, Duan X, Gao Y, Liu J, Zhang Y, Yang S, Qi LW, Wang L. Coordinated changes of gut microbiome and lipidome differentiates nonalcoholic steatohepatitis (NASH) from isolated steatosis. Liver Int 2020;40:622-37. [PMID: 31782595 DOI: 10.1111/liv.14316] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
120 Monserrat-Mesquida M, Quetglas-Llabrés M, Abbate M, Montemayor S, Mascaró CM, Casares M, Tejada S, Abete I, Zulet MA, Tur JA, Martínez JA, Sureda A. Oxidative Stress and Pro-Inflammatory Status in Patients with Non-Alcoholic Fatty Liver Disease. Antioxidants (Basel) 2020;9:E759. [PMID: 32824349 DOI: 10.3390/antiox9080759] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
121 Cotter TG, Rinella M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology 2020;158:1851-64. [PMID: 32061595 DOI: 10.1053/j.gastro.2020.01.052] [Cited by in Crossref: 120] [Cited by in F6Publishing: 136] [Article Influence: 60.0] [Reference Citation Analysis]
122 Luo Y, Wadhawan S, Greenfield A, Decato BE, Oseini AM, Collen R, Shevell DE, Thompson J, Jarai G, Charles ED, Sanyal AJ. SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH. Hepatol Commun 2021;5:760-73. [PMID: 34027267 DOI: 10.1002/hep4.1670] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
123 Muhammad N, Lembede BW, Erlwanger KH. Zingerone Administered Neonatally Prevents the Subsequent Development of High Dietary Fructose-Induced Fatty Liver in Sprague Dawley Rats. J Med Food 2021. [PMID: 33512269 DOI: 10.1089/jmf.2020.0189] [Reference Citation Analysis]
124 Shiffman ML. Approach to the patient with chronic hepatitis B and decompensated cirrhosis. Liver Int 2020;40 Suppl 1:22-6. [PMID: 32077612 DOI: 10.1111/liv.14359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
125 Tsuru H, Osaka M, Hiraoka Y, Yoshida M. HFD-induced hepatic lipid accumulation and inflammation are decreased in Factor D deficient mouse. Sci Rep 2020;10:17593. [PMID: 33067533 DOI: 10.1038/s41598-020-74617-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
126 Fatima K, Moeed A, Waqar E, Atif AR, Kamran A, Rizvi H, Suri NF, Haider H, Shuja SH, Khalid M, Minhas AMK. Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2021;:101816. [PMID: 34607067 DOI: 10.1016/j.clinre.2021.101816] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Boeckmans J, Natale A, Rombaut M, Buyl K, Rogiers V, De Kock J, Vanhaecke T, M Rodrigues R. Anti-NASH Drug Development Hitches a Lift on PPAR Agonism. Cells 2019;9:E37. [PMID: 31877771 DOI: 10.3390/cells9010037] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 9.7] [Reference Citation Analysis]
128 Cabrera D, Rao I, Raasch F, Solis N, Pizarro M, Freire M, Sáenz De Urturi D, Ramírez CA, Triantafilo N, León J, Riquelme A, Barrera F, Baudrand R, Aspichueta P, Arrese M, Arab JP. Mineralocorticoid receptor modulation by dietary sodium influences NAFLD development in mice. Ann Hepatol 2021;24:100357. [PMID: 33940220 DOI: 10.1016/j.aohep.2021.100357] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
129 Choudhry H. The Microbiome and Its Implications in Cancer Immunotherapy. Molecules 2021;26:E206. [PMID: 33401586 DOI: 10.3390/molecules26010206] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
130 Yang M, Ma F, Guan M. Role of Steroid Hormones in the Pathogenesis of Nonalcoholic Fatty Liver Disease. Metabolites 2021;11:320. [PMID: 34067649 DOI: 10.3390/metabo11050320] [Reference Citation Analysis]
131 Gebru YA, Choi MR, Raja G, Gupta H, Sharma SP, Choi YR, Kim HS, Yoon SJ, Kim DJ, Suk KT. Pathophysiological Roles of Mucosal-Associated Invariant T Cells in the Context of Gut Microbiota-Liver Axis. Microorganisms 2021;9:296. [PMID: 33535703 DOI: 10.3390/microorganisms9020296] [Reference Citation Analysis]
132 He LH, Yao DH, Wang LY, Zhang L, Bai XL. Gut Microbiome-Mediated Alteration of Immunity, Inflammation, and Metabolism Involved in the Regulation of Non-alcoholic Fatty Liver Disease. Front Microbiol 2021;12:761836. [PMID: 34795655 DOI: 10.3389/fmicb.2021.761836] [Reference Citation Analysis]
133 Xu P, Wang S, Pang D. A Novel Identified Peptide Hormone "Metabolitin" Attenuates Lipid Absorption in the Small Intestine of Diabetic Mice with Nonalcoholic Fatty Liver Disease by Regulating Neurotensin and AMPK Signaling Pathway. Evid Based Complement Alternat Med 2021;2021:8386848. [PMID: 34621326 DOI: 10.1155/2021/8386848] [Reference Citation Analysis]
134 Connelly MA, Velez Rivera J, Guyton JR, Siddiqui MS, Sanyal AJ. Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2020;52:619-36. [PMID: 32638417 DOI: 10.1111/apt.15935] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
135 Cremonini E, Iglesias DE, Kang J, Lombardo GE, Mostofinejad Z, Wang Z, Zhu W, Oteiza PI. (-)-Epicatechin and the comorbidities of obesity. Arch Biochem Biophys 2020;690:108505. [PMID: 32679195 DOI: 10.1016/j.abb.2020.108505] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
136 Fahlbusch P, Knebel B, Hörbelt T, Barbosa DM, Nikolic A, Jacob S, Al-Hasani H, Van de Velde F, Van Nieuwenhove Y, Müller-Wieland D, Lapauw B, Ouwens DM, Kotzka J. Physiological Disturbance in Fatty Liver Energy Metabolism Converges on IGFBP2 Abundance and Regulation in Mice and Men. Int J Mol Sci 2020;21:E4144. [PMID: 32532003 DOI: 10.3390/ijms21114144] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
137 Perez-Diaz-Del-Campo N, Marin-Alejandre BA, Cantero I, Monreal JI, Elorz M, Herrero JI, Benito-Boillos A, Riezu-Boj JI, Milagro FI, Tur JA, Martinez JA, Abete I, Zulet MA. Differential response to a 6-month energy-restricted treatment depending on SH2B1 rs7359397 variant in NAFLD subjects: Fatty Liver in Obesity (FLiO) Study. Eur J Nutr 2021;60:3043-57. [PMID: 33474638 DOI: 10.1007/s00394-020-02476-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
138 Pais R, Maurel T. Natural History of NAFLD. J Clin Med 2021;10:1161. [PMID: 33802047 DOI: 10.3390/jcm10061161] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
139 Ji L, Cai X, Bai Y, Li T. Application of a Novel Prediction Model for Predicting 2-Year Risk of Non-Alcoholic Fatty Liver Disease in the Non-Obese Population with Normal Blood Lipid Levels: A Large Prospective Cohort Study from China. Int J Gen Med 2021;14:2909-22. [PMID: 34234521 DOI: 10.2147/IJGM.S319759] [Reference Citation Analysis]
140 Lin S, Wang M, Liu Y, Huang J, Wu Y, Zhu Y, Wang X. Concurrence of HBV infection and non-alcoholic fatty liver disease is associated with higher prevalence of chronic kidney disease. Clin Res Hepatol Gastroenterol. 2021;45:101483. [PMID: 32646847 DOI: 10.1016/j.clinre.2020.06.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
141 Kim TH, Hong DG, Yang YM. Hepatokines and Non-Alcoholic Fatty Liver Disease: Linking Liver Pathophysiology to Metabolism. Biomedicines 2021;9:1903. [PMID: 34944728 DOI: 10.3390/biomedicines9121903] [Reference Citation Analysis]
142 Laudenslager M, Lazo M, Wang D, Selvin E, Chen PH, Pankow JS, Clark JM. Association between the soluble receptor for advanced glycation end products (sRAGE) and NAFLD in participants in the Atherosclerosis Risk in Communities Study. Dig Liver Dis 2021;53:873-8. [PMID: 33640303 DOI: 10.1016/j.dld.2021.02.005] [Reference Citation Analysis]
143 Li G, Rios RS, Wang XX, Yu Y, Zheng KI, Huang OY, Tang LJ, Ma HL, Jin Y, Targher G, Byrne CD, Pan XY, Zheng MH. Sex influences the association between appendicular skeletal muscle mass to visceral fat area ratio and non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease. Br J Nutr 2021;:1-8. [PMID: 34176541 DOI: 10.1017/S0007114521002415] [Reference Citation Analysis]
144 van Dijk AM, Dingerink S, Chilunga FP, Meeks KAC, Bahendeka S, Schulze MB, Danquah I, Osei TB, Serné E, Agyemang C, Holleboom AG. Metabolic-associated Fatty Liver Disease as Assessed by the Fatty Liver Index Among Migrant and Non-migrant Ghanaian Populations. J Clin Transl Hepatol 2021;9:494-502. [PMID: 34447678 DOI: 10.14218/JCTH.2021.00066] [Reference Citation Analysis]
145 Liu Y, Song J, Yang J, Zheng J, Yang L, Gao J, Tian S, Liu Z, Meng X, Wang JC, Dai Z, Tang YD. Tumor Necrosis Factor α-Induced Protein 8-Like 2 Alleviates Nonalcoholic Fatty Liver Disease Through Suppressing Transforming Growth Factor Beta-Activated Kinase 1 Activation. Hepatology 2021. [PMID: 33768585 DOI: 10.1002/hep.31832] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
146 Schmitz SM, Schooren L, Kroh A, Koch A, Stier C, Neumann UP, Ulmer TF, Alizai PH. Association of Body Composition and Sarcopenia with NASH in Obese Patients. J Clin Med 2021;10:3445. [PMID: 34362228 DOI: 10.3390/jcm10153445] [Reference Citation Analysis]
147 Yang Y, Zhang W, Wu X, Wu J, Sun C, Luo F, Pei Z. Systemic Overexpression of GDF5 in Adipocytes but Not Hepatocytes Alleviates High-Fat Diet-Induced Nonalcoholic Fatty Liver in Mice. Can J Gastroenterol Hepatol 2021;2021:8894685. [PMID: 33542911 DOI: 10.1155/2021/8894685] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
148 Wang M, Zhang R, Wang M, Zhang L, Ding Y, Tang Z, Wang H, Zhang W, Chen Y, Wang J. Genetic Polymorphism of Vitamin D Family Genes CYP2R1, CYP24A1, and CYP27B1 Are Associated With a High Risk of Non-alcoholic Fatty Liver Disease: A Case-Control Study. Front Genet 2021;12:717533. [PMID: 34484304 DOI: 10.3389/fgene.2021.717533] [Reference Citation Analysis]
149 Gerhardt F, Petroff D, Blank V, Böhlig A, van Bömmel F, Wittekind C, Berg T, Karlas T, Wiegand J. Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD). Scand J Gastroenterol 2020;55:706-11. [PMID: 32476514 DOI: 10.1080/00365521.2020.1766554] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
150 Pereira ENGDS, Paula DP, Araujo BP, Fonseca MJMD, Diniz MFHS, Daliry A, Griep RH. Advanced glycation end product: A potential biomarker for risk stratification of non-alcoholic fatty liver disease in ELSA-Brasil study. World J Gastroenterol 2021; 27(29): 4913-4928 [PMID: 34447235 DOI: 10.3748/wjg.v27.i29.4913] [Reference Citation Analysis]
151 Santos-Sánchez G, Cruz-Chamorro I, Álvarez-Ríos AI, Fernández-Santos JM, Vázquez-Román MV, Rodríguez-Ortiz B, Álvarez-Sánchez N, Álvarez-López AI, Millán-Linares MDC, Millán F, Pedroche J, Fernández-Pachón MS, Lardone PJ, Guerrero JM, Bejarano I, Carrillo-Vico A. Lupinus angustifolius Protein Hydrolysates Reduce Abdominal Adiposity and Ameliorate Metabolic Associated Fatty Liver Disease (MAFLD) in Western Diet Fed-ApoE-/- Mice. Antioxidants (Basel) 2021;10:1222. [PMID: 34439470 DOI: 10.3390/antiox10081222] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
152 Wang S, Tao J, Chen H, Kandadi MR, Sun M, Xu H, Lopaschuk GD, Lu Y, Zheng J, Peng H, Ren J. Ablation of Akt2 and AMPKα2 rescues high fat diet-induced obesity and hepatic steatosis through Parkin-mediated mitophagy. Acta Pharm Sin B 2021;11:3508-26. [PMID: 34900533 DOI: 10.1016/j.apsb.2021.07.006] [Reference Citation Analysis]
153 Cho EJ, Yu SJ, Jung GC, Kwak MS, Yang JI, Yim JY, Chung GE. Body weight gain rather than body weight variability associated with increased risk of nonalcoholic fatty liver disease. Sci Rep 2021;11:14428. [PMID: 34257374 DOI: 10.1038/s41598-021-93883-5] [Reference Citation Analysis]
154 Jorgačević B, Vučević D, Vesković M, Mladenović D, Vukićević D, Vukićević RJ, Todorović V, Radosavljević T. The effect of cannabinoid receptor 1 blockade on adipokine and proinflammatory cytokine concentration in adipose and hepatic tissue in mice with nonalcoholic fatty liver disease. Can J Physiol Pharmacol 2019;97:120-9. [PMID: 30673308 DOI: 10.1139/cjpp-2018-0607] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
155 Ibrahim SH. Sinusoidal endotheliopathy in nonalcoholic steatohepatitis: therapeutic implications. Am J Physiol Gastrointest Liver Physiol 2021;321:G67-74. [PMID: 34037463 DOI: 10.1152/ajpgi.00009.2021] [Reference Citation Analysis]
156 Jepsen P, Younossi ZM. The global burden of cirrhosis: A review of disability-adjusted life-years lost and unmet needs. J Hepatol 2021;75 Suppl 1:S3-S13. [PMID: 34039490 DOI: 10.1016/j.jhep.2020.11.042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
157 Radun R, Trauner M. Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities. Semin Liver Dis 2021. [PMID: 34289507 DOI: 10.1055/s-0041-1731707] [Reference Citation Analysis]
158 Tanase DM, Gosav EM, Petrov D, Jucan AE, Lacatusu CM, Floria M, Tarniceriu CC, Costea CF, Ciocoiu M, Rezus C. Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets. Diagnostics (Basel) 2021;11:2053. [PMID: 34829402 DOI: 10.3390/diagnostics11112053] [Reference Citation Analysis]
159 Hui Lim GE, Tang A, Ng CH, Chin YH, Lim WH, Hao Tan DJ, Yong JN, Xiao J, Wen-Min Lee C, Chan M, Chew NW, Xuan Tan EX, Siddiqui MS, Huang D, Noureddin M, Sanyal AJ, Muthiah MD. An Observational Data Meta-Analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01276-3. [PMID: 34871813 DOI: 10.1016/j.cgh.2021.11.038] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
160 Chen LZ, Jing XB, Wu CF, Zeng YC, Xie YC, Wang MQ, Chen WX, Hu X, Zhou YN, Cai XB. Nonalcoholic Fatty Liver Disease-Associated Liver Fibrosis Is Linked with the Severity of Coronary Artery Disease Mediated by Systemic Inflammation. Dis Markers 2021;2021:6591784. [PMID: 34992694 DOI: 10.1155/2021/6591784] [Reference Citation Analysis]
161 Kimura T, Tanaka N, Fujimori N, Yamazaki T, Katsuyama T, Iwashita Y, Pham J, Joshita S, Pydi SP, Umemura T. Serum thrombospondin 2 is a novel predictor for the severity in the patients with NAFLD. Liver Int 2021;41:505-14. [PMID: 33386676 DOI: 10.1111/liv.14776] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
162 Gellert-Kristensen H, Richardson TG, Davey Smith G, Nordestgaard BG, Tybjaerg-Hansen A, Stender S. Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population. Hepatology 2020;72:845-56. [PMID: 32190914 DOI: 10.1002/hep.31238] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 37.0] [Reference Citation Analysis]
163 Kubota R, Hayashi N, Kinoshita K, Saito T, Ozaki K, Ueda Y, Tsuchishima M, Tsutsumi M, George J. Inhibition of γ-glutamyltransferase ameliorates ischaemia-reoxygenation tissue damage in rats with hepatic steatosis. Br J Pharmacol 2020;177:5195-207. [PMID: 32910829 DOI: 10.1111/bph.15258] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
164 Umbro I, Baratta F, Angelico F, Del Ben M. Nonalcoholic Fatty Liver Disease and the Kidney: A Review. Biomedicines 2021;9:1370. [PMID: 34680486 DOI: 10.3390/biomedicines9101370] [Reference Citation Analysis]
165 Li P, Yan K, Chang X, Chen X, Wang R, Fan X, Tang T, Zhan D, Qi K. Sex-specific maternal calcium requirements for the prevention of nonalcoholic fatty liver disease by altering the intestinal microbiota and lipid metabolism in the high-fat-diet-fed offspring mice. Gut Microbes 2020;11:1590-607. [PMID: 32576050 DOI: 10.1080/19490976.2020.1768645] [Reference Citation Analysis]
166 Yang M, Khoukaz L, Qi X, Kimchi ET, Staveley-O'Carroll KF, Li G. Diet and Gut Microbiota Interaction-Derived Metabolites and Intrahepatic Immune Response in NAFLD Development and Treatment. Biomedicines 2021;9:1893. [PMID: 34944709 DOI: 10.3390/biomedicines9121893] [Reference Citation Analysis]
167 Roeb E. Excess Body Weight and Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD). Visc Med 2021;37:273-80. [PMID: 34540943 DOI: 10.1159/000515445] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
168 Di Ciaula A, Baj J, Garruti G, Celano G, De Angelis M, Wang HH, Di Palo DM, Bonfrate L, Wang DQ, Portincasa P. Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk. J Clin Med 2020;9:E2648. [PMID: 32823983 DOI: 10.3390/jcm9082648] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
169 Paquette M, Yan M, Ramírez-Reyes JMJ, El-Houjeiri L, Biondini M, Dufour CR, Jeong H, Pacis A, Giguère V, Estall JL, Siegel PM, Audet-Walsh É, Pause A. Loss of hepatic Flcn protects against fibrosis and inflammation by activating autophagy pathways. Sci Rep 2021;11:21268. [PMID: 34711912 DOI: 10.1038/s41598-021-99958-7] [Reference Citation Analysis]
170 Arrese M, Barrera F, Triantafilo N, Arab JP. Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations. Expert Review of Gastroenterology & Hepatology 2019;13:849-66. [DOI: 10.1080/17474124.2019.1649981] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
171 Marques V, Afonso MB, Bierig N, Duarte-Ramos F, Santos-Laso Á, Jimenez-Agüero R, Eizaguirre E, Bujanda L, Pareja MJ, Luís R, Costa A, Machado MV, Alonso C, Arretxe E, Alustiza JM, Krawczyk M, Lammert F, Tiniakos DG, Flehmig B, Cortez-Pinto H, Banales JM, Castro RE, Normann A, Rodrigues CMP. Adiponectin, Leptin, and IGF-1 Are Useful Diagnostic and Stratification Biomarkers of NAFLD. Front Med (Lausanne) 2021;8:683250. [PMID: 34249975 DOI: 10.3389/fmed.2021.683250] [Reference Citation Analysis]
172 Allaire M, Gilgenkrantz H. The aged liver: Beyond cellular senescence. Clin Res Hepatol Gastroenterol 2020;44:6-11. [PMID: 31427197 DOI: 10.1016/j.clinre.2019.07.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
173 Zhou Z, Zhang Q, Wu W, Lin YH, Tai DI, Tseng JH, Lin YR, Wu S, Tsui PH. Hepatic steatosis assessment using ultrasound homodyned-K parametric imaging: the effects of estimators. Quant Imaging Med Surg 2019;9:1932-47. [PMID: 31929966 DOI: 10.21037/qims.2019.08.03] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
174 Murakami E, Nakahara T, Hiramatsu A, Morio K, Fujino H, Yamauchi M, Kawaoka T, Tsuge M, Imamura M, Aikata H, Fudeyasu K, Nakashima Y, Iwaki D, Jodai D, Ohigashi T, Nishimura Y, Minamoto Y, Nagao A, Yoneda M, Saeki Y, Tanabe K, Ohdan H, Chayama K. Therapeutic effects of sleeve gastrectomy for non-alcoholic steatohepatitis estimated by paired liver biopsy in morbidly obese Japanese patients. Medicine (Baltimore) 2021;100:e26436. [PMID: 34190166 DOI: 10.1097/MD.0000000000026436] [Reference Citation Analysis]
175 Teresa Borrello M, Rita Emma M, Listi A, Rubis M, Coslet S, Augello G, Cusimano A, Cabibi D, Porcasi R, Giannitrapani L, Soresi M, Pantuso G, Blyth K, Montalto G, Pin C, Cervello M, Iovanna J. NUPR1 protects liver from lipotoxic injury by improving the endoplasmic reticulum stress response. FASEB J 2021;35:e21395. [PMID: 33566371 DOI: 10.1096/fj.202002413RR] [Reference Citation Analysis]
176 White GE, Richardson GA, Mair C, Courcoulas AP, King WC. Do Associations Between Alcohol Use and Alcohol Use Disorder Vary by Weight Status? Results From the National Epidemiologic Survey on Alcohol and Related Conditions-III. Alcohol Clin Exp Res 2019;43:1498-509. [PMID: 31034607 DOI: 10.1111/acer.14071] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
177 Mandala A, Janssen RC, Palle S, Short KR, Friedman JE. Pediatric Non-Alcoholic Fatty Liver Disease: Nutritional Origins and Potential Molecular Mechanisms. Nutrients 2020;12:E3166. [PMID: 33081177 DOI: 10.3390/nu12103166] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
178 Siddiqui MT, Amin H, Garg R, Chadalavada P, Al-Yaman W, Lopez R, Singh A. Medications in type-2 diabetics and their association with liver fibrosis. World J Gastroenterol 2020; 26(23): 3249-3259 [PMID: 32684739 DOI: 10.3748/wjg.v26.i23.3249] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
179 Bullón-Vela V, Abete I, Zulet MA, Xu Y, Martínez-González MA, Sayón-Orea C, Ruiz-Canela M, Toledo E, Sánchez VM, Estruch R, Lamuela-Raventós RM, Almanza-Aguilera E, Fitó M, Salas-Salvadó J, Díaz-López A, Tinahones FJ, Tur JA, Romaguera D, Konieczna J, Pintó X, Daimiel L, Rodriguez-Mateos A, Alfredo Martínez J. Urinary Resveratrol Metabolites Output: Differential Associations with Cardiometabolic Markers and Liver Enzymes in House-Dwelling Subjects Featuring Metabolic Syndrome. Molecules 2020;25:E4340. [PMID: 32971870 DOI: 10.3390/molecules25184340] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
180 Serrano OK, Peterson KJ, Vock DM, Berglund D, Kandaswamy R, Lake JR, Pruett TL, Chinnakotla S. Clinical Impact of Antecedent Bariatric Surgery on Liver Transplant Outcomes: A Retrospective Matched Case-control Study. Transplantation 2021;105:1280-4. [PMID: 32590608 DOI: 10.1097/TP.0000000000003378] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
181 Liu J, Yuan Y, Gong X, Zhang L, Zhou Q, Wu S, Zhang X, Hu J, Kuang G, Yin X, Wan J, Yuan Y. Baicalin and its nanoliposomes ameliorates nonalcoholic fatty liver disease via suppression of TLR4 signaling cascade in mice. Int Immunopharmacol 2020;80:106208. [PMID: 31955065 DOI: 10.1016/j.intimp.2020.106208] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
182 Ignat MV, Coldea TE, Salanță LC, Mudura E. Plants of the Spontaneous Flora with Beneficial Action in the Management of Diabetes, Hepatic Disorders, and Cardiovascular Disease. Plants (Basel) 2021;10:216. [PMID: 33498684 DOI: 10.3390/plants10020216] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
183 Taskinen MR, Packard CJ, Borén J. Dietary Fructose and the Metabolic Syndrome. Nutrients 2019;11:E1987. [PMID: 31443567 DOI: 10.3390/nu11091987] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 18.7] [Reference Citation Analysis]
184 Longo L, de Souza VEG, Stein DJ, de Freitas JS, Uribe-Cruz C, Torres ILS, Álvares-da-Silva MR. Transcranial direct current stimulation (tDCS) has beneficial effects on liver lipid accumulation and hepatic inflammatory parameters in obese rats. Sci Rep 2021;11:11037. [PMID: 34040131 DOI: 10.1038/s41598-021-90563-2] [Reference Citation Analysis]
185 He X, Hu Y, Liu W, Zhu G, Zhang R, You J, Shao Y, Li Y, Zhang Z, Cui J, He Y, Ge G, Yang H. Deciphering the Effective Constituents and Mechanisms of Portulaca oleracea L. for Treating NASH via Integrating Bioinformatics Analysis and Experimental Pharmacology. Front Pharmacol 2022;12:818227. [DOI: 10.3389/fphar.2021.818227] [Reference Citation Analysis]
186 Louala S, Lamri-Senhadji M. Beneficial Effects of Low-Calorie-Carbohydrate/High-Agar Diet on Cardiometabolic Disorders Associated with Non-Alcoholic Fatty Liver Disease in Obese Rats. Prev Nutr Food Sci 2019;24:400-9. [PMID: 31915635 DOI: 10.3746/pnf.2019.24.4.400] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
187 Kang SH, Lee HW, Yoo JJ, Cho Y, Kim SU, Lee TH, Jang BK, Kim SG, Ahn SB, Kim H, Jun DW, Choi JI, Song DS, Kim W, Jeong SW, Kim MY, Koh H, Jeong S, Lee JW, Cho YK; Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:363-401. [PMID: 34154309 DOI: 10.3350/cmh.2021.0178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
188 Labenz C, Huber Y, Michel M, Nagel M, Galle PR, Kostev K, Schattenberg JM. Nonalcoholic Fatty Liver Disease Increases the Risk of Anxiety and Depression. Hepatol Commun 2020;4:1293-301. [PMID: 32923833 DOI: 10.1002/hep4.1541] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
189 Tavaglione F, De Vincentis A, Bruni V, Gallo IF, Carotti S, Tuccinardi D, Spagnolo G, Ciociola E, Mancina RM, Jamialahmadi O, D'Alessio R, Bottazzi B, Manfrini S, Picardi A, Perrone G, Pozzilli P, Caricato M, Vespasiani-Gentilucci U, Romeo S. Accuracy of controlled attenuation parameter for assessing liver steatosis in individuals with morbid obesity before bariatric surgery. Liver Int 2021. [PMID: 34890093 DOI: 10.1111/liv.15127] [Reference Citation Analysis]
190 Golabi P, Paik JM, Arshad T, Younossi Y, Mishra A, Younossi ZM. Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities. Hepatol Commun 2020;4:1136-48. [PMID: 32766474 DOI: 10.1002/hep4.1534] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
191 Wang C, Cai Z, Deng X, Li H, Zhao Z, Guo C, Zhang P, Li L, Gu T, Yang L, Zhao L, Wang D, Yuan G. Association of Hepatic Steatosis Index and Fatty Liver Index with Carotid Atherosclerosis in Type 2 Diabetes. Int J Med Sci 2021;18:3280-9. [PMID: 34400897 DOI: 10.7150/ijms.62010] [Reference Citation Analysis]
192 Tilinca MC, Tiuca RA, Niculas C, Varga A, Tilea I. Future perspectives in diabesity treatment: Semaglutide, a glucagon-like peptide 1 receptor agonist (Review). Exp Ther Med 2021;22:1167. [PMID: 34504612 DOI: 10.3892/etm.2021.10601] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
193 Ni X, Jiao L, Zhang Y, Xu J, Zhang Y, Zhang X, Du Y, Sun Z, Wang S. Relationship Between Non-Alcoholic Fatty Liver Disease and Abdominal and Pericardial Adipose Tissue in Middle-Aged and Elderly Subjects. Int J Gen Med 2021;14:3439-44. [PMID: 34285567 DOI: 10.2147/IJGM.S317081] [Reference Citation Analysis]
194 Saadati S, Sadeghi A, Mansour A, Yari Z, Poustchi H, Hedayati M, Hatami B, Hekmatdoost A. Curcumin and inflammation in non-alcoholic fatty liver disease: a randomized, placebo controlled clinical trial. BMC Gastroenterol. 2019;19:133. [PMID: 31345163 DOI: 10.1186/s12876-019-1055-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
195 Guo Q, Furuta K, Lucien F, Gutierrez Sanchez LH, Hirsova P, Krishnan A, Kabashima A, Pavelko KD, Madden B, Alhuwaish H, Gao Y, Revzin A, Ibrahim SH. Integrin β1-enriched extracellular vesicles mediate monocyte adhesion and promote liver inflammation in murine NASH. J Hepatol 2019;71:1193-205. [PMID: 31433301 DOI: 10.1016/j.jhep.2019.07.019] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 13.7] [Reference Citation Analysis]
196 Abbate M, Montemayor S, Mascaró CM, Casares M, Gómez C, Ugarriza L, Tejada S, Abete I, Zulet MÁ, Sureda A, Martínez JA, Tur JA. Albuminuria Is Associated with Hepatic Iron Load in Patients with Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome. J Clin Med 2021;10:3187. [PMID: 34300354 DOI: 10.3390/jcm10143187] [Reference Citation Analysis]
197 Longo M, Meroni M, Paolini E, Erconi V, Carli F, Fortunato F, Ronchi D, Piciotti R, Sabatini S, Macchi C, Alisi A, Miele L, Soardo G, Comi GP, Valenti L, Ruscica M, Fracanzani AL, Gastaldelli A, Dongiovanni P. TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models. Cell Mol Gastroenterol Hepatol 2021:S2352-345X(21)00241-1. [PMID: 34823063 DOI: 10.1016/j.jcmgh.2021.11.007] [Reference Citation Analysis]
198 Parisinos CA, Wilman HR, Thomas EL, Kelly M, Nicholls RC, McGonigle J, Neubauer S, Hingorani AD, Patel RS, Hemingway H, Bell JD, Banerjee R, Yaghootkar H. Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis. J Hepatol 2020;73:241-51. [PMID: 32247823 DOI: 10.1016/j.jhep.2020.03.032] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
199 Moszak M, Szulińska M, Walczak-Gałęzewska M, Bogdański P. Nutritional Approach Targeting Gut Microbiota in NAFLD-To Date. Int J Environ Res Public Health 2021;18:1616. [PMID: 33567710 DOI: 10.3390/ijerph18041616] [Reference Citation Analysis]
200 Delgado GE, Kleber ME, Moissl AP, Yazdani B, Kusnik A, Ebert MP, März W, Krämer BK, Lammert A, Teufel A. Surrogate scores of advanced fibrosis in NAFLD/NASH do not predict mortality in patients with medium-to-high cardiovascular risk. Am J Physiol Gastrointest Liver Physiol 2021;321:G252-61. [PMID: 34132110 DOI: 10.1152/ajpgi.00058.2021] [Reference Citation Analysis]
201 Yoshino K, Hosooka T, Shinohara M, Aoki C, Hosokawa Y, Imamori M, Ogawa W. Canagliflozin ameliorates hepatic fat deposition in obese diabetic mice: Role of prostaglandin E2. Biochem Biophys Res Commun 2021;557:62-8. [PMID: 33862461 DOI: 10.1016/j.bbrc.2021.04.012] [Reference Citation Analysis]
202 De Vincentis A, Tavaglione F, Spagnuolo R, Pujia R, Tuccinardi D, Mascianà G, Picardi A, Antonelli Incalzi R, Valenti L, Romeo S, Vespasiani-Gentilucci U. Metabolic and genetic determinants for progression to severe liver disease in subjects with obesity from the UK Biobank. Int J Obes (Lond) 2021. [PMID: 34750514 DOI: 10.1038/s41366-021-01015-w] [Reference Citation Analysis]
203 Manco M, Panera N, Crudele A, Braghini MR, Bianchi M, Comparcola D, De Vito R, Maggiore G, Alisi A. Angiopoietin-2 levels correlates with disease activity in children with nonalcoholic fatty liver disease. Pediatr Res 2021. [PMID: 34331020 DOI: 10.1038/s41390-021-01666-5] [Reference Citation Analysis]
204 Liebe R, Esposito I, Bock HH, Vom Dahl S, Stindt J, Baumann U, Luedde T, Keitel V. Diagnosis and management of secondary causes of steatohepatitis. J Hepatol 2021;74:1455-71. [PMID: 33577920 DOI: 10.1016/j.jhep.2021.01.045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
205 Ji C, Guo X. The clinical potential of circulating microRNAs in obesity. Nat Rev Endocrinol 2019;15:731-43. [PMID: 31611648 DOI: 10.1038/s41574-019-0260-0] [Cited by in Crossref: 49] [Cited by in F6Publishing: 56] [Article Influence: 16.3] [Reference Citation Analysis]
206 Shengir M, Krishnamurthy S, Ghali P, Deschenes M, Wong P, Chen T, Sebastiani G. Prevalence and predictors of nonalcoholic fatty liver disease in South Asian women with polycystic ovary syndrome. World J Gastroenterol 2020; 26(44): 7046-7060 [PMID: 33311949 DOI: 10.3748/wjg.v26.i44.7046] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
207 DiStefano JK. Fructose-mediated effects on gene expression and epigenetic mechanisms associated with NAFLD pathogenesis. Cell Mol Life Sci 2020;77:2079-90. [PMID: 31760464 DOI: 10.1007/s00018-019-03390-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
208 Mauri E, Gori M, Giannitelli SM, Zancla A, Mozetic P, Abbruzzese F, Merendino N, Gigli G, Rossi F, Trombetta M, Rainer A. Nano-encapsulation of hydroxytyrosol into formulated nanogels improves therapeutic effects against hepatic steatosis: An in vitro study. Mater Sci Eng C Mater Biol Appl 2021;124:112080. [PMID: 33947572 DOI: 10.1016/j.msec.2021.112080] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
209 Longo L, Tonin Ferrari J, Rampelotto PH, Hirata Dellavia G, Pasqualotto A, P Oliveira C, Thadeu Schmidt Cerski C, Reverbel da Silveira T, Uribe-Cruz C, Álvares-da-Silva MR. Gut Dysbiosis and Increased Intestinal Permeability Drive microRNAs, NLRP-3 Inflammasome and Liver Fibrosis in a Nutritional Model of Non-Alcoholic Steatohepatitis in Adult Male Sprague Dawley Rats. Clin Exp Gastroenterol 2020;13:351-68. [PMID: 32982365 DOI: 10.2147/CEG.S262879] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
210 Chen H. Nutrient mTORC1 signaling contributes to hepatic lipid metabolism in the pathogenesis of non-alcoholic fatty liver disease. Liver Research 2020;4:15-22. [DOI: 10.1016/j.livres.2020.02.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
211 Soret PA, Magusto J, Housset C, Gautheron J. In Vitro and In Vivo Models of Non-Alcoholic Fatty Liver Disease: A Critical Appraisal. J Clin Med 2020;10:E36. [PMID: 33374435 DOI: 10.3390/jcm10010036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
212 Li X, Hong J, Wang Y, Pei M, Wang L, Gong Z. Trimethylamine-N-Oxide Pathway: A Potential Target for the Treatment of MAFLD. Front Mol Biosci 2021;8:733507. [PMID: 34660695 DOI: 10.3389/fmolb.2021.733507] [Reference Citation Analysis]
213 Knebel B, Fahlbusch P, Dille M, Wahlers N, Hartwig S, Jacob S, Kettel U, Schiller M, Herebian D, Koellmer C, Lehr S, Müller-Wieland D, Kotzka J. Fatty Liver Due to Increased de novo Lipogenesis: Alterations in the Hepatic Peroxisomal Proteome. Front Cell Dev Biol 2019;7:248. [PMID: 31709254 DOI: 10.3389/fcell.2019.00248] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
214 Zhou X, Yuan Y, Teng F, Li K, Luo S, Zhang P, Liu D, Zhang H, Zhang J. Obesity-induced upregulation of microRNA-183-5p promotes hepatic triglyceride accumulation by targeting the B-cell translocation gene 1. Life Sci 2021;268:119011. [PMID: 33421522 DOI: 10.1016/j.lfs.2020.119011] [Reference Citation Analysis]
215 Stacchiotti A, Grossi I, García-Gómez R, Patel GA, Salvi A, Lavazza A, De Petro G, Monsalve M, Rezzani R. Melatonin Effects on Non-Alcoholic Fatty Liver Disease Are Related to MicroRNA-34a-5p/Sirt1 Axis and Autophagy. Cells 2019;8:E1053. [PMID: 31500354 DOI: 10.3390/cells8091053] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
216 Dungubat E, Watabe S, Togashi-Kumagai A, Watanabe M, Kobayashi Y, Harada N, Yamaji R, Fukusato T, Lodon G, Sevjid B, Takahashi Y. Effects of Caffeine and Chlorogenic Acid on Nonalcoholic Steatohepatitis in Mice Induced by Choline-Deficient, L-Amino Acid-Defined, High-Fat Diet. Nutrients 2020;12:E3886. [PMID: 33353230 DOI: 10.3390/nu12123886] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
217 Barr RG, Cestone A, De Silvestri A. A Pre-Release Algorithm With a Confidence Map for Estimating the Attenuation Coefficient for Liver Fat Quantification. J Ultrasound Med 2021. [PMID: 34730847 DOI: 10.1002/jum.15870] [Reference Citation Analysis]
218 Ramos VM, Kowaltowski AJ, Kakimoto PA. Autophagy in Hepatic Steatosis: A Structured Review. Front Cell Dev Biol 2021;9:657389. [PMID: 33937257 DOI: 10.3389/fcell.2021.657389] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
219 Zhang L, Zhang Z, Li C, Zhu T, Gao J, Zhou H, Zheng Y, Chang Q, Wang M, Wu J, Ran L, Wu Y, Miao H, Zou X, Liang B. S100A11 Promotes Liver Steatosis via FOXO1-Mediated Autophagy and Lipogenesis. Cell Mol Gastroenterol Hepatol 2021;11:697-724. [PMID: 33075563 DOI: 10.1016/j.jcmgh.2020.10.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
220 Meroni M, Longo M, Dongiovanni P. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies. Nutrients. 2019;11. [PMID: 31689910 DOI: 10.3390/nu11112642] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
221 Fontes-Cal TCM, Mattos RT, Medeiros NI, Pinto BF, Belchior-Bezerra M, Roque-Souza B, Dutra WO, Ferrari TCA, Vidigal PVT, Faria LC, Couto CA, Gomes JAS. Crosstalk Between Plasma Cytokines, Inflammation, and Liver Damage as a New Strategy to Monitoring NAFLD Progression. Front Immunol 2021;12:708959. [PMID: 34447378 DOI: 10.3389/fimmu.2021.708959] [Reference Citation Analysis]
222 Ghadieh HE, Abu Helal R, Muturi HT, Issa DD, Russo L, Abdallah SL, Najjar JA, Benencia F, Vazquez G, Li W, Najjar SM. Loss of Hepatic Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Links Nonalcoholic Steatohepatitis to Atherosclerosis. Hepatol Commun 2020;4:1591-609. [PMID: 33163831 DOI: 10.1002/hep4.1590] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
223 Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell'Obesità (SIO)., Members of the guidelines panel., Coordinator., AISF Members., SID Members., SIO Members., Metodologists. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Dig Liver Dis 2021:S1590-8658(21)00214-0. [PMID: 34924319 DOI: 10.1016/j.dld.2021.04.029] [Reference Citation Analysis]
224 Ryou M, Stylopoulos N, Baffy G. Nonalcoholic fatty liver disease and portal hypertension. Explor Med 2020;1:149-69. [PMID: 32685936 DOI: 10.37349/emed.2020.00011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
225 Moon J, Kong E, Lee J, Jung J, Kim E, Park SB, Kim P. Intravital longitudinal imaging of hepatic lipid droplet accumulation in a murine model for nonalcoholic fatty liver disease. Biomed Opt Express 2020;11:5132-46. [PMID: 33014604 DOI: 10.1364/BOE.395890] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
226 Schmitz SM, Kroh A, Koch A, Brozat JF, Stier C, Neumann UP, Ulmer TF, Alizai PH. Comparison of Liver Recovery After Sleeve Gastrectomy and Roux-en-Y-Gastric Bypass. Obes Surg 2021;31:3218-26. [PMID: 33813683 DOI: 10.1007/s11695-021-05390-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
227 Qi H, Hu C, Wang S, Zhang Y, Du R, Zhang J, Lin L, Wang T, Zhao Z, Li M, Xu Y, Xu M, Bi Y, Wang W, Chen Y, Lu J. Early life famine exposure, adulthood obesity patterns and the risk of nonalcoholic fatty liver disease. Liver Int 2020;40:2694-705. [PMID: 32558201 DOI: 10.1111/liv.14572] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
228 Zou J, Xiong H, Zhang H, Hu C, Lu S, Zou Y. Association between the cardiometabolic index and non-alcoholic fatty liver disease: insights from a general population. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02099-y] [Reference Citation Analysis]
229 Rustgi VK, Li Y, John T, Catalano C, Elsaid MI. Health Care Resource Use and Cost Burden of Chronic Kidney Disease in Patients With Chronic Liver Disease: A Real-World Claims Analysis. Hepatol Commun. 2020;4:1404-1418. [PMID: 33024912 DOI: 10.1002/hep4.1573] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
230 Alberti G, Gana JC, Santos JL. Fructose, Omega 3 Fatty Acids, and Vitamin E: Involvement in Pediatric Non-Alcoholic Fatty Liver Disease. Nutrients 2020;12:E3531. [PMID: 33212947 DOI: 10.3390/nu12113531] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
231 Li H, Dun Y, Zhang W, You B, Liu Y, Fu S, Qiu L, Cheng J, Ripley-Gonzalez JW, Liu S. Exercise improves lipid droplet metabolism disorder through activation of AMPK-mediated lipophagy in NAFLD. Life Sci 2021;273:119314. [PMID: 33667513 DOI: 10.1016/j.lfs.2021.119314] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
232 Baumann A, Nier A, Hernández-Arriaga A, Brandt A, Lorenzo Pisarello MJ, Jin CJ, Pilar E, Camarinha-Silva A, Schattenberg JM, Bergheim I. Toll-like receptor 1 as a possible target in non-alcoholic fatty liver disease. Sci Rep 2021;11:17815. [PMID: 34497333 DOI: 10.1038/s41598-021-97346-9] [Reference Citation Analysis]
233 Li L, Yang L, Yang F, Zhao XL, Xue S, Gong FH. Ginkgo biloba Extract 50 (GBE50) Ameliorates Insulin Resistance, Hepatic Steatosis and Liver Injury in High Fat Diet-Fed Mice. J Inflamm Res 2021;14:1959-71. [PMID: 34040411 DOI: 10.2147/JIR.S302934] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
234 Yang C, Wan M, Xu D, Pan D, Xia H, Yang L, Sun G. Flaxseed Powder Attenuates Non-Alcoholic Steatohepatitis via Modulation of Gut Microbiota and Bile Acid Metabolism through Gut-Liver Axis. Int J Mol Sci 2021;22:10858. [PMID: 34639207 DOI: 10.3390/ijms221910858] [Reference Citation Analysis]
235 Spearman CW, Afihene M, Betiku O, Bobat B, Cunha L, Kassianides C, Katsidzira L, Mekonnen HD, Ocama P, Ojo O, Paruk I, Tzeuton C, Sonderup MW; Gastroenterology and Hepatology Association of sub-Saharan Africa (GHASSA). Epidemiology, risk factors, social determinants of health, and current management for non-alcoholic fatty liver disease in sub-Saharan Africa. Lancet Gastroenterol Hepatol 2021;6:1036-46. [PMID: 34508671 DOI: 10.1016/S2468-1253(21)00275-2] [Reference Citation Analysis]
236 Bourebaba L, Marycz K. Pathophysiological Implication of Fetuin-A Glycoprotein in the Development of Metabolic Disorders: A Concise Review. J Clin Med 2019;8:E2033. [PMID: 31766373 DOI: 10.3390/jcm8122033] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
237 Rana R, Shearer AM, Fletcher EK, Nguyen N, Guha S, Cox DH, Abdelmalek M, Wang Y, Baleja JD, Covic L, Kuliopulos A. PAR2 controls cholesterol homeostasis and lipid metabolism in nonalcoholic fatty liver disease. Mol Metab 2019;29:99-113. [PMID: 31668396 DOI: 10.1016/j.molmet.2019.08.019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
238 Vuppalanchi R, Noureddin M, Alkhouri N, Sanyal AJ. Therapeutic pipeline in nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol 2021;18:373-92. [PMID: 33568794 DOI: 10.1038/s41575-020-00408-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
239 Albhaisi SAM, Bajaj JS, Sanyal AJ. Role of gut microbiota in liver disease. Am J Physiol Gastrointest Liver Physiol 2020;318:G84-98. [PMID: 31657225 DOI: 10.1152/ajpgi.00118.2019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
240 Huber Y, Labenz C, Michel M, Wörns MA, Galle PR, Kostev K, Schattenberg JM. Tumor Incidence in Patients with Non-Alcoholic Fatty Liver Disease. Dtsch Arztebl Int 2020;117:719-24. [PMID: 33559592 DOI: 10.3238/arztebl.2020.0719] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
241 Kasper P, Breuer S, Hoffmann T, Vohlen C, Janoschek R, Schmitz L, Appel S, Fink G, Hünseler C, Quaas A, Demir M, Lang S, Steffen HM, Martin A, Schramm C, Bürger M, Mahabir E, Goeser T, Dötsch J, Hucklenbruch-Rother E, Bae-Gartz I. Maternal Exercise Mediates Hepatic Metabolic Programming via Activation of AMPK-PGC1α Axis in the Offspring of Obese Mothers. Cells 2021;10:1247. [PMID: 34069390 DOI: 10.3390/cells10051247] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
242 Xu L, Xie J, Chen S, Chen Y, Yang H, Miao M, Zhu Z, Li Y, Yu C, Xu C. Light-to-Moderate Alcohol Consumption Is Associated With Increased Risk of Type 2 Diabetes in Individuals With Nonalcoholic Fatty Liver Disease: A Nine-Year Cohort Study. Am J Gastroenterol 2020;115:876-84. [PMID: 32282335 DOI: 10.14309/ajg.0000000000000607] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
243 Rahman MM, Kibria MG, Begum H, Haque M, Sultana N, Akhter M, Rowshon AHM, Ahmed F, Hasan M. Prevalence, risk factors and metabolic profile of the non-obese and obese non-alcoholic fatty liver disease in a rural community of South Asia. BMJ Open Gastroenterol 2020;7:e000535. [PMID: 33376110 DOI: 10.1136/bmjgast-2020-000535] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
244 Lin X, Liou YH, Li Y, Gong L, Li Y, Hao Y, Pham B, Xu S, Jiang Z, Li L, Peng Y, Qiao D, Lin H, Liu P, Wei W, Zhang G, Lee CH, Zhou X. FAM13A Represses AMPK Activity and Regulates Hepatic Glucose and Lipid Metabolism. iScience 2020;23:100928. [PMID: 32151973 DOI: 10.1016/j.isci.2020.100928] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
245 Jensen VS, Fledelius C, Zachodnik C, Damgaard J, Nygaard H, Tornqvist KS, Kirk RK, Viuff BM, Wulff EM, Lykkesfeldt J, Hvid H. Insulin treatment improves liver histopathology and decreases expression of inflammatory and fibrogenic genes in a hyperglycemic, dyslipidemic hamster model of NAFLD. J Transl Med 2021;19:80. [PMID: 33596938 DOI: 10.1186/s12967-021-02729-1] [Reference Citation Analysis]
246 Lee YH, Cho Y, Lee BW, Park CY, Lee DH, Cha BS, Rhee EJ. Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis. Diabetes Metab J. 2019;43:31-45. [PMID: 30793550 DOI: 10.4093/dmj.2019.0011] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 20.0] [Reference Citation Analysis]
247 Lin A, Roth H, Anyane-Yeboa A, Rubin DT, Paul S. Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis 2021;27:947-55. [PMID: 32780094 DOI: 10.1093/ibd/izaa189] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
248 Hliwa A, Ramos-Molina B, Laski D, Mika A, Sledzinski T. The Role of Fatty Acids in Non-Alcoholic Fatty Liver Disease Progression: An Update. Int J Mol Sci 2021;22:6900. [PMID: 34199035 DOI: 10.3390/ijms22136900] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
249 Yu H, Yang F, Zhong W, Jiang X, Zhang F, Ji X, Xue M, Qiu Y, Yu J, Hu X, Chen J, Bao Z. Secretory Galectin-3 promotes hepatic steatosis via regulation of the PPARγ/CD36 signaling pathway. Cell Signal 2021;84:110043. [PMID: 33991615 DOI: 10.1016/j.cellsig.2021.110043] [Reference Citation Analysis]
250 Arconzo M, Piccinin E, Moschetta A. Increased risk of acute liver failure by pain killer drugs in NAFLD: Focus on nuclear receptors and their coactivators. Dig Liver Dis 2021;53:26-34. [PMID: 32546444 DOI: 10.1016/j.dld.2020.05.034] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
251 Moon AM, Singal AG, Tapper EB. Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clin Gastroenterol Hepatol. 2020;18:2650-2666. [PMID: 31401364 DOI: 10.1016/j.cgh.2019.07.060] [Cited by in Crossref: 102] [Cited by in F6Publishing: 110] [Article Influence: 34.0] [Reference Citation Analysis]
252 Wang Q, Shi X, Wang J, Zhang J, Xu C. Low serum vitamin D concentrations are associated with obese but not lean NAFLD: a cross-sectional study. Nutr J 2021;20:30. [PMID: 33794916 DOI: 10.1186/s12937-021-00690-9] [Reference Citation Analysis]
253 Alamri AS, Alhomrani M, Alsanie WF, Alghamdi AJ, Alghamdi ZM, Al-Subaie AA, Alharthi YA, Alqurashi HH, Asdaq SMB. Prevalence and predictors of non-alcoholic fatty liver disease in tertiary care hospital of Taif, Saudi Arabia: A retrospective study. Saudi J Biol Sci 2021;28:4921-5. [PMID: 34466067 DOI: 10.1016/j.sjbs.2021.05.063] [Reference Citation Analysis]
254 Peng Z, Gong Y, Wang X, He W, Wu L, Zhang L, Xiong L, Huang Y, Su L, Shi P, Cao X, Liu R, Li Y, Xiao H. METTL3-m6A-Rubicon axis inhibits autophagy in nonalcoholic fatty liver disease. Mol Ther 2021:S1525-0016(21)00471-8. [PMID: 34547464 DOI: 10.1016/j.ymthe.2021.09.016] [Reference Citation Analysis]
255 Qian X, Wang T, Gong J, Wang L, Chen X, Lin H, Tu W, Jiang S, Li S. Exercise in mice ameliorates high-fat diet-induced nonalcoholic fatty liver disease by lowering HMGCS2. Aging (Albany NY) 2021;13:8960-74. [PMID: 33647884 DOI: 10.18632/aging.202717] [Reference Citation Analysis]
256 Praktiknjo M, Djayadi N, Mohr R, Schierwagen R, Bischoff J, Dold L, Pohlmann A, Schwarze-Zander C, Wasmuth JC, Boesecke C, Rockstroh JK, Trebicka J. Fibroblast growth factor 21 is independently associated with severe hepatic steatosis in non-obese HIV-infected patients. Liver Int. 2019;39:1514-1520. [PMID: 30916873 DOI: 10.1111/liv.14107] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
257 Ansari S, Haboubi H, Haboubi N. Adult obesity complications: challenges and clinical impact. Ther Adv Endocrinol Metab 2020;11:2042018820934955. [PMID: 32612803 DOI: 10.1177/2042018820934955] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
258 Xia M, Sun X, Zheng L, Bi Y, Li Q, Sun L, Di F, Li H, Zhu D, Gao Y, Bao Y, Wang Y, He L, Wu B, Wang S, Gao J, Gao X, Bian H. Regional difference in the susceptibility of non-alcoholic fatty liver disease in China. BMJ Open Diabetes Res Care 2020;8:e001311. [PMID: 32522731 DOI: 10.1136/bmjdrc-2020-001311] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
259 Ratjen I, Morze J, Enderle J, Both M, Borggrefe J, Müller HP, Kassubek J, Koch M, Lieb W. Adherence to a plant-based diet in relation to adipose tissue volumes and liver fat content. Am J Clin Nutr 2020;112:354-63. [PMID: 32453423 DOI: 10.1093/ajcn/nqaa119] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
260 Lang S, Martin A, Zhang X, Farowski F, Wisplinghoff H, J G T Vehreschild M, Krawczyk M, Nowag A, Kretzschmar A, Scholz C, Kasper P, Roderburg C, Mohr R, Lammert F, Tacke F, Schnabl B, Goeser T, Steffen HM, Demir M. Combined analysis of gut microbiota, diet and PNPLA3 polymorphism in biopsy-proven non-alcoholic fatty liver disease. Liver Int 2021;41:1576-91. [PMID: 33896117 DOI: 10.1111/liv.14899] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
261 Ocker M. Challenges and opportunities in drug development for nonalcoholic steatohepatitis. Eur J Pharmacol 2020;870:172913. [PMID: 31926994 DOI: 10.1016/j.ejphar.2020.172913] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
262 Abdelmoneim D, El-Adl M, El-Sayed G, El-Sherbini ES. Protective effect of fenofibrate against high-fat-high-fructose diet induced non-obese NAFLD in rats. Fundam Clin Pharmacol 2021;35:379-88. [PMID: 32757283 DOI: 10.1111/fcp.12597] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
263 Sinn DH, Kang D, Cho SJ, Paik SW, Guallar E, Cho J, Gwak GY. Risk of hepatocellular carcinoma in individuals without traditional risk factors: development and validation of a novel risk score. Int J Epidemiol 2020;49:1562-71. [PMID: 32725117 DOI: 10.1093/ije/dyaa089] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
264 Ivancovsky-Wajcman D, Fliss-Isakov N, Salomone F, Webb M, Shibolet O, Kariv R, Zelber-Sagi S. Dietary vitamin E and C intake is inversely associated with the severity of nonalcoholic fatty liver disease. Dig Liver Dis 2019;51:1698-705. [PMID: 31281067 DOI: 10.1016/j.dld.2019.06.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
265 Adlanmerini M, Krusen BM, Nguyen HCB, Teng CW, Woodie LN, Tackenberg MC, Geisler CE, Gaisinsky J, Peed LC, Carpenter BJ, Hayes MR, Lazar MA. REV-ERB nuclear receptors in the suprachiasmatic nucleus control circadian period and restrict diet-induced obesity. Sci Adv 2021;7:eabh2007. [PMID: 34705514 DOI: 10.1126/sciadv.abh2007] [Reference Citation Analysis]
266 Zhang M, Nie X, Yuan Y, Wang Y, Ma X, Yin J, Bao Y. Osteocalcin Alleviates Nonalcoholic Fatty Liver Disease in Mice through GPRC6A. Int J Endocrinol 2021;2021:9178616. [PMID: 33531899 DOI: 10.1155/2021/9178616] [Reference Citation Analysis]
267 Jiang X, Zheng J, Zhang S, Wang B, Wu C, Guo X. Advances in the Involvement of Gut Microbiota in Pathophysiology of NAFLD. Front Med (Lausanne) 2020;7:361. [PMID: 32850884 DOI: 10.3389/fmed.2020.00361] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
268 Kubota N, Ojima H, Hatano M, Yamazaki K, Masugi Y, Tsujikawa H, Fujii-Nishimura Y, Ueno A, Kurebayashi Y, Shinoda M, Kitago M, Abe Y, Kitagawa Y, Sakamoto M. Clinicopathological features of hepatocellular carcinoma with fatty change: Tumors with macrovesicular steatosis have better prognosis and aberrant expression patterns of perilipin and adipophilin. Pathol Int 2020;70:199-209. [PMID: 31930673 DOI: 10.1111/pin.12889] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
269 Wilson RB, Chen YJ, Sutherland BG, Sawyez CG, Zhang R, Woolnough T, Hetherington AM, Peters KM, Patel K, Kennelly JP, Leonard KA, Schuurman M, Jacobs RL, Wang R, Borradaile NM. The marine compound and elongation factor 1A1 inhibitor, didemnin B, provides benefit in western diet-induced non-alcoholic fatty liver disease. Pharmacol Res 2020;161:105208. [PMID: 32977024 DOI: 10.1016/j.phrs.2020.105208] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
270 Chiriac S, Stanciu C, Girleanu I, Cojocariu C, Sfarti C, Singeap AM, Cuciureanu T, Huiban L, Muzica CM, Zenovia S, Nastasa R, Trifan A. Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter. Can J Gastroenterol Hepatol 2021;2021:6696857. [PMID: 33505944 DOI: 10.1155/2021/6696857] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
271 Xia Y, Zhang S, Zhang Q, Liu L, Meng G, Wu H, Bao X, Gu Y, Sun S, Wang X, Zhou M, Jia Q, Song K, Wu Q, Niu K, Zhao Y. Insoluble dietary fibre intake is associated with lower prevalence of newly-diagnosed non-alcoholic fatty liver disease in Chinese men: a large population-based cross-sectional study. Nutr Metab (Lond) 2020;17:4. [PMID: 31956330 DOI: 10.1186/s12986-019-0420-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
272 Rennert C, Heil T, Schicht G, Stilkerich A, Seidemann L, Kegel-Hübner V, Seehofer D, Damm G. Prolonged Lipid Accumulation in Cultured Primary Human Hepatocytes Rather Leads to ER Stress than Oxidative Stress. Int J Mol Sci 2020;21:E7097. [PMID: 32993055 DOI: 10.3390/ijms21197097] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
273 Di Ciaula A, Carbone F, Shanmugham H, Molina-Molina E, Bonfrate L, Ministrini S, Montecucco F, Portincasa P. Adiponectin involved in portal flow hepatic extraction of 13C-methacetin in obesity and non-alcoholic fatty liver. Eur J Intern Med 2021;89:56-64. [PMID: 33867228 DOI: 10.1016/j.ejim.2021.03.036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
274 Hao L, Wang Z, Wang Y, Wang J, Zeng Z. Association between Cardiorespiratory Fitness, Relative Grip Strength with Non-Alcoholic Fatty Liver Disease. Med Sci Monit 2020;26:e923015. [PMID: 32555123 DOI: 10.12659/MSM.923015] [Reference Citation Analysis]
275 Ore A, Akinloye OA, Adeogun AI, Ugbaja RN, Morifi E, Makatini M, Moepya R, Mbhele T. Buchholzia coriacea seed (wonderful kolanut) alleviates insulin resistance, steatosis, inflammation and oxidative stress in high fat diet model of fatty liver disease. J Food Biochem 2021;:e13836. [PMID: 34184286 DOI: 10.1111/jfbc.13836] [Reference Citation Analysis]
276 Furuta K, Guo Q, Hirsova P, Ibrahim SH. Emerging Roles of Liver Sinusoidal Endothelial Cells in Nonalcoholic Steatohepatitis. Biology (Basel) 2020;9:E395. [PMID: 33198153 DOI: 10.3390/biology9110395] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
277 Zembroski AS, Buhman KK, Aryal UK. Proteome and phosphoproteome characterization of liver in the postprandial state from diet-induced obese and lean mice. J Proteomics 2021;232:104072. [PMID: 33309929 DOI: 10.1016/j.jprot.2020.104072] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
278 Teng Y, Zhao Z, Tasnim F, Huang X, Yu H. A scalable and sensitive steatosis chip with long-term perfusion of in situ differentiated HepaRG organoids. Biomaterials 2021;275:120904. [PMID: 34119888 DOI: 10.1016/j.biomaterials.2021.120904] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
279 Barchetta I, Cimini FA, Chiappetta C, Bertoccini L, Ceccarelli V, Capoccia D, Gaggini M, Di Cristofano C, Della Rocca C, Silecchia G, Leonetti F, Lenzi A, Gastaldelli A, Cavallo MG. Relationship between hepatic and systemic angiopoietin-like 3, hepatic Vitamin D receptor expression and NAFLD in obesity. Liver Int 2020;40:2139-47. [PMID: 32510837 DOI: 10.1111/liv.14554] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
280 Lima RP, Nunes PIG, Viana AFSC, Oliveira FTB, Silva RAC, Alves APNN, Viana DA, Fonseca SGC, Carvalho AA, Chaves MH, Rao VS, Santos FA. α,β-Amyrin prevents steatosis and insulin resistance in a high-fat diet-induced mouse model of NAFLD via the AMPK-mTORC1-SREBP1 signaling mechanism. Braz J Med Biol Res 2021;54:e11391. [PMID: 34406209 DOI: 10.1590/1414-431X2021e11391] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
281 Chen L, Lang AL, Poff GD, Ding WX, Beier JI. Vinyl chloride-induced interaction of nonalcoholic and toxicant-associated steatohepatitis: Protection by the ALDH2 activator Alda-1. Redox Biol 2019;24:101205. [PMID: 31026768 DOI: 10.1016/j.redox.2019.101205] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
282 Nelson Hayes C, Zhang P, Chayama K; Department of Gastroenterology and Metabolism, Graduate School of Biomedical & Health Sciences, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Minami-ku, Hiroshima, Japan, Department of Gastroenterology and Metabolism, Graduate School of Biomedical & Health Sciences, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Minami-ku, Hiroshima, Japan, Department of Gastroenterology and Metabolism, Graduate School of Biomedical & Health Sciences, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Minami-ku, Hiroshima, Japan. The Role of Lipids in Hepatocellular Carcinoma. In: Tirnitz-parker JE, editor. Hepatocellular Carcinoma. Codon Publications; 2019. pp. 95-110. [DOI: 10.15586/hepatocellularcarcinoma.2019.ch5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
283 Kan J, Zhao C, Lu S, Shen G, Yang J, Tong P, Xi L, Zhang R, Liang X, Su D, Li D, Liu Y. S100A16, a novel lipogenesis promoting factor in livers of mice and hepatocytes in vitro. J Cell Physiol 2019;234:21395-406. [DOI: 10.1002/jcp.28748] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
284 Chopyk DM, Grakoui A. Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders. Gastroenterology 2020;159:849-63. [PMID: 32569766 DOI: 10.1053/j.gastro.2020.04.077] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 11.0] [Reference Citation Analysis]
285 Younossi ZM, Henry L. The Impact of Obesity and Type 2 Diabetes on Chronic Liver Disease.Am J Gastroenterol. 2019;114:1714-1715. [PMID: 31599742 DOI: 10.14309/ajg.0000000000000433] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
286 Yu H, Jiang X, Dong F, Zhang F, Ji X, Xue M, Yang F, Chen J, Hu X, Bao Z. Lipid accumulation-induced hepatocyte senescence regulates the activation of hepatic stellate cells through the Nrf2-antioxidant response element pathway. Exp Cell Res 2021;405:112689. [PMID: 34107274 DOI: 10.1016/j.yexcr.2021.112689] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
287 Asakawa M, Itoh M, Suganami T, Sakai T, Kanai S, Shirakawa I, Yuan X, Hatayama T, Shimada S, Akiyama Y, Fujiu K, Inagaki Y, Manabe I, Yamaoka S, Yamada T, Tanaka S, Ogawa Y. Upregulation of cancer-associated gene expression in activated fibroblasts in a mouse model of non-alcoholic steatohepatitis. Sci Rep 2019;9:19601. [PMID: 31862949 DOI: 10.1038/s41598-019-56039-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
288 Nelson SM, Hoskins JD, Lisanti C, Chaudhuri J. Ultrasound Fatty Liver Indicator: A Simple Tool for Differentiating Steatosis From Nonalcoholic Steatohepatitis: Validity in the Average Obese Population. J Ultrasound Med 2020;39:749-59. [PMID: 31647137 DOI: 10.1002/jum.15154] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
289 Zhang S, Meng G, Zhang Q, Liu L, Yao Z, Wu H, Gu Y, Wang Y, Zhang T, Wang X, Zhang J, Sun S, Wang X, Zhou M, Jia Q, Song K, Wang Y, Qi L, Niu K. Consumption of Preserved Egg Is Associated with Modestly Increased Risk of Nonalcoholic Fatty Liver Disease in Chinese Adults. J Nutr 2021:nxab163. [PMID: 34049388 DOI: 10.1093/jn/nxab163] [Reference Citation Analysis]
290 Yu X, Chen C, Guo Y, Tong Y, Zhao Y, Wu L, Sun X, Wu X, Song Z. High NAFLD fibrosis score in non-alcoholic fatty liver disease as a predictor of carotid plaque development: a retrospective cohort study based on regular health check-up data in China. Ann Med 2021;53:1621-31. [PMID: 34498502 DOI: 10.1080/07853890.2021.1974081] [Reference Citation Analysis]
291 Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism 2020;111S:154170. [PMID: 32006558 DOI: 10.1016/j.metabol.2020.154170] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 29.0] [Reference Citation Analysis]
292 Ajayi F, Jan J, Singal AG, Rich NE. Racial and Sex Disparities in Hepatocellular Carcinoma in the USA. Curr Hepatol Rep 2020;19:462-9. [PMID: 33828937 DOI: 10.1007/s11901-020-00554-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
293 Liu H, Xu J, Li H, Zhang L, Xu P. Network pharmacology-based investigation to explore the effect and mechanism of Erchen decoction against the nonalcoholic fatty liver disease. Anat Rec (Hoboken) 2021;304:2605-19. [PMID: 34536264 DOI: 10.1002/ar.24770] [Reference Citation Analysis]
294 Afonso MB, Castro RE, Rodrigues CMP. Processes exacerbating apoptosis in non-alcoholic steatohepatitis. Clin Sci (Lond) 2019;133:2245-64. [PMID: 31742325 DOI: 10.1042/CS20190068] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
295 Phisalprapa P, Prasitwarachot R, Kositamongkol C, Hengswat P, Srivanichakorn W, Washirasaksiri C, Treeprasertsuk S, Charatcharoenwitthaya P, Chaiyakunapruk N. Economic burden of non-alcoholic steatohepatitis with significant fibrosis in Thailand. BMC Gastroenterol 2021;21:135. [PMID: 33765931 DOI: 10.1186/s12876-021-01720-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
296 Morrill KE, Crocker RM, Hingle MD, Thomson CA, Garcia DO. Awareness, Knowledge, and Misperceptions Related to Nonalcoholic Fatty Liver Disease in a Community Sample of Mexican-Origin Women: A Mixed Methods Study. Front Public Health 2021;9:626428. [PMID: 34485209 DOI: 10.3389/fpubh.2021.626428] [Reference Citation Analysis]
297 Helal RA, Russo L, Ghadieh HE, Muturi HT, Asalla S, Lee AD, Gatto-Weis C, Najjar SM. Regulation of hepatic fibrosis by carcinoembryonic antigen-related cell adhesion molecule 1. Metabolism 2021;121:154801. [PMID: 34058224 DOI: 10.1016/j.metabol.2021.154801] [Reference Citation Analysis]
298 Lee SM, Muratalla J, Diaz-Ruiz A, Remon-Ruiz P, McCann M, Liew CW, Kineman RD, Cordoba-Chacon J. Rosiglitazone Requires Hepatocyte PPARγ Expression to Promote Steatosis in Male Mice With Diet-Induced Obesity. Endocrinology 2021;162:bqab175. [PMID: 34417811 DOI: 10.1210/endocr/bqab175] [Reference Citation Analysis]
299 Wang L, Zhi Y, Ye Y, Zhang M, Ma X, Tie H, Ma X, Zheng N, Xia W, Song Y. Identify Molecular Mechanisms of Jiangzhi Decoction on Nonalcoholic Fatty Liver Disease by Network Pharmacology Analysis and Experimental Validation. Biomed Res Int 2020;2020:8829346. [PMID: 33415161 DOI: 10.1155/2020/8829346] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
300 Tang K, Deng Y, Zheng C, Nie H, Pan M, Chen R, Xie J, Yang Q, Zhang Y. Prevention of Nonalcoholic Hepatic Steatosis by Shenling Baizhu Powder: Involvement of Adiponectin-Induced Inhibition of Hepatic SREBP-1c. Oxid Med Cell Longev 2020;2020:9701285. [PMID: 33062150 DOI: 10.1155/2020/9701285] [Reference Citation Analysis]
301 Shi YX, Chen XY, Qiu HN, Jiang WR, Zhang MY, Huang YP, Ji YP, Zhang S, Li CJ, Lin JN. Visceral fat area to appendicular muscle mass ratio as a predictor for nonalcoholic fatty liver disease independent of obesity. Scand J Gastroenterol 2021;56:312-20. [PMID: 33535004 DOI: 10.1080/00365521.2021.1879244] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
302 Jiang Y, Chowdhury S, Xu BH, Meybodi MA, Damiris K, Devalaraju S, Pyrsopoulos N. Nonalcoholic fatty liver disease is associated with worse intestinal complications in patients hospitalized for Clostridioides difficile infection. World J Hepatol 2021; 13(11): 1777-1790 [PMID: 34904045 DOI: 10.4254/wjh.v13.i11.1777] [Reference Citation Analysis]
303 Allen AM, Hicks SB, Mara KC, Larson JJ, Therneau TM. The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - A longitudinal cohort study. J Hepatol 2019;71:1229-36. [PMID: 31470068 DOI: 10.1016/j.jhep.2019.08.018] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 16.0] [Reference Citation Analysis]
304 Xue Y, Liu H, Yang XX, Pang L, Liu J, Ng KTP, Yeung OWH, Lam YF, Zhang WY, Lo CM, Man K. Inhibition of Carnitine Palmitoyltransferase 1A Aggravates Fatty Liver Graft Injury via Promoting Mitochondrial Permeability Transition. Transplantation 2021;105:550-60. [PMID: 32890136 DOI: 10.1097/TP.0000000000003437] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
305 Arab JP, Díaz LA, Dirchwolf M, Mark H, Lazarus JV, Vaughan E, Méndez-Sánchez N, de Oliveira CP, Gadano A, Arrese M. NAFLD: Challenges and opportunities to address the public health challenge in Latin America. Ann Hepatol 2021;24:100359. [PMID: 34004366 DOI: 10.1016/j.aohep.2021.100359] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
306 Um YJ, Chang Y, Jung HS, Cho IY, Shin JH, Shin H, Wild SH, Byrne CD, Ryu S. Sleep Duration, Sleep Quality, and the Development of Nonalcoholic Fatty Liver Disease: A Cohort Study. Clin Transl Gastroenterol 2021;12:e00417. [PMID: 34665792 DOI: 10.14309/ctg.0000000000000417] [Reference Citation Analysis]
307 Camacho-Muñoz D, Kiezel-Tsugunova M, Kiss O, Uddin M, Sundén M, Ryaboshapkina M, Lind L, Oscarsson J, Nicolaou A. Omega-3 carboxylic acids and fenofibrate differentially alter plasma lipid mediators in patients with non-alcoholic fatty liver disease. FASEB J 2021;35:e21976. [PMID: 34618982 DOI: 10.1096/fj.202100380RRR] [Reference Citation Analysis]
308 Kuroda H, Fujiwara Y, Abe T, Nagasawa T, Oguri T, Noguchi S, Kamiyama N, Takikawa Y. Two-dimensional shear wave elastography and ultrasound-guided attenuation parameter for progressive non-alcoholic steatohepatitis. PLoS One 2021;16:e0249493. [PMID: 33826669 DOI: 10.1371/journal.pone.0249493] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
309 Xia MF, Chen LY, Wu L, Ma H, Li Q, Aleteng Q, Hu Y, He WY, Gao J, Lin HD, Gao X. The PNPLA3 rs738409 C>G variant influences the association between low skeletal muscle mass and NAFLD: the Shanghai Changfeng Study. Aliment Pharmacol Ther 2019;50:684-95. [PMID: 31250467 DOI: 10.1111/apt.15372] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
310 Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Schattenberg JM, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut. 2020;. [PMID: 33303564 DOI: 10.1136/gutjnl-2020-323082] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
311 Pafili K, Roden M. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Mol Metab 2021;50:101122. [PMID: 33220492 DOI: 10.1016/j.molmet.2020.101122] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
312 Piras IS, Gerhard GS, DiStefano JK. Palmitate and Fructose Interact to Induce Human Hepatocytes to Produce Pro-Fibrotic Transcriptional Responses in Hepatic Stellate Cells Exposed to Conditioned Media. Cell Physiol Biochem 2020;54:1068-82. [PMID: 33095528 DOI: 10.33594/000000288] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
313 Zhou F, She W, He L, Zhu J, Gu L. The effect of anthocyanins supplementation on liver enzymes among patients with metabolic disorders: A systematic review and meta-analysis of randomized clinical trials. Phytother Res 2021. [PMID: 34510592 DOI: 10.1002/ptr.7280] [Reference Citation Analysis]
314 Ballestri S, Nascimbeni F, Lugari S, Lonardo A, Francica G. A critical appraisal of the use of ultrasound in hepatic steatosis. Expert Rev Gastroenterol Hepatol 2019;13:667-81. [PMID: 31104523 DOI: 10.1080/17474124.2019.1621164] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
315 Kupriyanova Y, Zaharia OP, Bobrov P, Karusheva Y, Burkart V, Szendroedi J, Hwang JH, Roden M; GDS group. Early changes in hepatic energy metabolism and lipid content in recent-onset type 1 and 2 diabetes mellitus. J Hepatol 2021;74:1028-37. [PMID: 33259845 DOI: 10.1016/j.jhep.2020.11.030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
316 Yabiku K, Nakamoto K, Tsubakimoto M. Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glucose Metabolism, Liver Function, Ascites, and Hemodynamics in a Mouse Model of Nonalcoholic Steatohepatitis and Type 2 Diabetes. J Diabetes Res 2020;2020:1682904. [PMID: 33457424 DOI: 10.1155/2020/1682904] [Reference Citation Analysis]
317 Cai Q, Gan C, Tang C, Wu H, Gao J. Mechanism and Therapeutic Opportunities of Histone Modifications in Chronic Liver Disease. Front Pharmacol 2021;12:784591. [PMID: 34887768 DOI: 10.3389/fphar.2021.784591] [Reference Citation Analysis]
318 Xin FZ, Zhao ZH, Zhang RN, Pan Q, Gong ZZ, Sun C, Fan JG. Folic acid attenuates high-fat diet-induced steatohepatitis via deacetylase SIRT1-dependent restoration of PPARα. World J Gastroenterol 2020; 26(18): 2203-2220 [PMID: 32476787 DOI: 10.3748/wjg.v26.i18.2203] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
319 Funuyet-Salas J, Pérez-San-Gregorio MÁ, Martín-Rodríguez A, Romero-Gómez M. Quality of Life and Coping in Nonalcoholic Fatty Liver Disease: Influence of Diabetes and Obesity. Int J Environ Res Public Health 2021;18:3503. [PMID: 33800585 DOI: 10.3390/ijerph18073503] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
320 Li B, Cheng Y, Yu S, Zang L, Yin Y, Liu J, Zhang L, Mu Y. Human Umbilical Cord-Derived Mesenchymal Stem Cell Therapy Ameliorates Nonalcoholic Fatty Liver Disease in Obese Type 2 Diabetic Mice. Stem Cells Int 2019;2019:8628027. [PMID: 31781248 DOI: 10.1155/2019/8628027] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
321 Shanmugam H, Di Ciaula A, Di Palo DM, Molina-Molina E, Garruti G, Faienza MF, vanErpecum K, Portincasa P. Multiplying effects of COVID-19 lockdown on metabolic risk and fatty liver. Eur J Clin Invest 2021;51:e13597. [PMID: 34032283 DOI: 10.1111/eci.13597] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
322 Wu D, Liu Z, Wang Y, Zhang Q, Li J, Zhong P, Xie Z, Ji A, Li Y. Epigallocatechin-3-Gallate Alleviates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease via Inhibition of Apoptosis and Promotion of Autophagy through the ROS/MAPK Signaling Pathway. Oxid Med Cell Longev 2021;2021:5599997. [PMID: 33953830 DOI: 10.1155/2021/5599997] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
323 Zhang Q, Ma X, Xing J, Shi H, Yang R, Jiao Y, Chen S, Wu S, Zhang S, Sun X. Serum Uric Acid Is a Mediator of the Association Between Obesity and Incident Nonalcoholic Fatty Liver Disease: A Prospective Cohort Study. Front Endocrinol (Lausanne) 2021;12:657856. [PMID: 34054728 DOI: 10.3389/fendo.2021.657856] [Reference Citation Analysis]
324 Jiang QQ, Liu BB, Xu KS. New insights into BMP9 signaling in liver diseases. Mol Cell Biochem 2021;476:3591-600. [PMID: 34019202 DOI: 10.1007/s11010-021-04182-6] [Reference Citation Analysis]
325 Sardi C, Martini E, Mello T, Camelliti S, Sfondrini L, Marcucci F, Kallikourdis M, Sommariva M, Rumio C. Effect of acetylsalicylic acid on inflamed adipose tissue. Insulin resistance and hepatic steatosis in a mouse model of diet-induced obesity. Life Sci 2021;264:118618. [PMID: 33141040 DOI: 10.1016/j.lfs.2020.118618] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
326 Di Costanzo A, Ronca A, D'Erasmo L, Manfredini M, Baratta F, Pastori D, Di Martino M, Ceci F, Angelico F, Del Ben M, Pavanello C, Turri M, Calabresi L, Favari E, Arca M. HDL-Mediated Cholesterol Efflux and Plasma Loading Capacities Are Altered in Subjects with Metabolically- but Not Genetically Driven Non-Alcoholic Fatty Liver Disease (NAFLD). Biomedicines 2020;8:E625. [PMID: 33352841 DOI: 10.3390/biomedicines8120625] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
327 De Vincentis A, Tavaglione F, Jamialahmadi O, Picardi A, Antonelli Incalzi R, Valenti L, Romeo S, Vespasiani-Gentilucci U. A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00595-4. [PMID: 34091049 DOI: 10.1016/j.cgh.2021.05.056] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
328 Boga S, Koksal AR, Sen İ, Kurul Yeniay M, Yilmaz Ozguven MB, Serin E, Erturk SM, Alkim H, Alkim C. Liver and pancreas: 'Castor and Pollux' regarding the relationship between hepatic steatosis and pancreas exocrine insufficiency. Pancreatology 2020;20:880-6. [PMID: 32475757 DOI: 10.1016/j.pan.2020.04.020] [Reference Citation Analysis]
329 Mendez-sanchez N, Arrese M, Gadano A, Oliveira CP, Fassio E, Arab JP, Chávez-tapia NC, Dirchwolf M, Torre A, Ridruejo E, Pinchemel-cotrim H, Castellanos Fernández MI, Uribe M, Girala M, Diaz-ferrer J, Restrepo JC, Padilla-machaca M, Dagher L, Gatica M, Olaechea B, Pessôa MG, Silva M. The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. The Lancet Gastroenterology & Hepatology 2021;6:65-72. [DOI: 10.1016/s2468-1253(20)30340-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 15] [Article Influence: 32.0] [Reference Citation Analysis]
330 Amernia B, Moosavy SH, Banookh F, Zoghi G. FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran. BMC Gastroenterol 2021;21:453. [PMID: 34861841 DOI: 10.1186/s12876-021-02038-3] [Reference Citation Analysis]
331 Chai TYL, Rajaratnam RM, Deng D, George J, Pasupathy D, Cheung NW. The prevalence of gestational diabetes mellitus in women diagnosed with non-alcoholic fatty liver disease during pregnancy: A systematic review and meta-analysis. J Diabetes Complications 2021;35:107991. [PMID: 34219018 DOI: 10.1016/j.jdiacomp.2021.107991] [Reference Citation Analysis]
332 Miele L, Perna A, Dajko M, Zocco MA, De Magistris A, Nicoletti TF, Biolato M, Marrone G, Liguori A, Maccora D, Valenza V, Rossi S, Riso V, Di Natale D, Gasbarrini A, Grieco A, Silvestri G. Clinical characteristics of metabolic associated fatty liver disease (MAFLD) in subjects with myotonic dystrophy type 1 (DM1). Digestive and Liver Disease 2021. [DOI: 10.1016/j.dld.2020.12.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
333 Machado MV. Aerobic Exercise in the Management of Metabolic Dysfunction Associated Fatty Liver Disease. Diabetes Metab Syndr Obes 2021;14:3627-45. [PMID: 34408459 DOI: 10.2147/DMSO.S304357] [Reference Citation Analysis]
334 Wang X, Li Q, Pang J, Lin J, Liu Y, Xu Z, Zhang H, Shen T, Chen X, Ma J, Xu X, Ling W, Chen Y. Associations between serum total, free and bioavailable testosterone and non-alcoholic fatty liver disease in community-dwelling middle-aged and elderly women. Diabetes Metab 2021;47:101199. [PMID: 33058967 DOI: 10.1016/j.diabet.2020.09.007] [Reference Citation Analysis]
335 Sun DQ, Jin Y, Wang TY, Zheng KI, Rios RS, Zhang HY, Targher G, Byrne CD, Yuan WJ, Zheng MH. MAFLD and risk of CKD. Metabolism 2021;115:154433. [PMID: 33212070 DOI: 10.1016/j.metabol.2020.154433] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 12.0] [Reference Citation Analysis]
336 Zarei M, Pizarro-Delgado J, Barroso E, Palomer X, Vázquez-Carrera M. Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis. Trends Pharmacol Sci 2020;41:199-208. [PMID: 31980251 DOI: 10.1016/j.tips.2019.12.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
337 Carter JK, Bhattacharya D, Borgerding JN, Fiel MI, Faith JJ, Friedman SL. Modeling dysbiosis of human NASH in mice: Loss of gut microbiome diversity and overgrowth of Erysipelotrichales. PLoS One 2021;16:e0244763. [PMID: 33395434 DOI: 10.1371/journal.pone.0244763] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
338 Jullian-Desayes I, Trzepizur W, Boursier J, Joyeux-Faure M, Bailly S, Benmerad M, Le Vaillant M, Jaffre S, Pigeanne T, Bizieux-Thaminy A, Humeau MP, Alizon C, Goupil F, Costentin C, Gaucher J, Tamisier R, Gagnadoux F, Pépin JL. Obstructive sleep apnea, chronic obstructive pulmonary disease and NAFLD: an individual participant data meta-analysis. Sleep Med 2021;77:357-64. [PMID: 32843301 DOI: 10.1016/j.sleep.2020.04.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
339 Xu H, Wang L. The Role of Notch Signaling Pathway in Non-Alcoholic Fatty Liver Disease. Front Mol Biosci 2021;8:792667. [PMID: 34901163 DOI: 10.3389/fmolb.2021.792667] [Reference Citation Analysis]
340 Loomba R, Morgan E, Watts L, Xia S, Hannan LA, Geary RS, Baker BF, Bhanot S. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol 2020;5:829-38. [PMID: 32553151 DOI: 10.1016/S2468-1253(20)30186-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
341 Mills EL, Harmon C, Jedrychowski MP, Xiao H, Garrity R, Tran NV, Bradshaw GA, Fu A, Szpyt J, Reddy A, Prendeville H, Danial NN, Gygi SP, Lynch L, Chouchani ET. UCP1 governs liver extracellular succinate and inflammatory pathogenesis. Nat Metab 2021;3:604-17. [PMID: 34002097 DOI: 10.1038/s42255-021-00389-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
342 Briand F, Heymes C, Bonada L, Angles T, Charpentier J, Branchereau M, Brousseau E, Quinsat M, Fazilleau N, Burcelin R, Sulpice T. A 3-week nonalcoholic steatohepatitis mouse model shows elafibranor benefits on hepatic inflammation and cell death. Clin Transl Sci 2020;13:529-38. [PMID: 31981449 DOI: 10.1111/cts.12735] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
343 Park M, Kang C, Lee HJ. Effect of Bombyx mori on the Liver Protection of Non-Alcoholic Fatty Liver Disease Based on In Vitro and In Vivo Models. Curr Issues Mol Biol 2021;43:3. [PMID: 33925122 DOI: 10.3390/cimb43010003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
344 Cossiga V, Lembo V, Guarino M, Tuccillo C, Morando F, Pontillo G, Fiorentino A, Caporaso N, Morisco F. Berberis aristata, Elaeis guineensis and Coffea canephora Extracts Modulate the Insulin Receptor Expression and Improve Hepatic Steatosis in NAFLD Patients: A Pilot Clinical Trial. Nutrients 2019;11:3070. [DOI: 10.3390/nu11123070] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
345 Altajar S, Baffy G. Skeletal Muscle Dysfunction in the Development and Progression of Nonalcoholic Fatty Liver Disease. J Clin Transl Hepatol 2020;8:414-23. [PMID: 33447525 DOI: 10.14218/JCTH.2020.00065] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
346 Hu DS, Zhu SH, Li X, Chen QF, Lin CJ, Fang DH, Wu JS. Association between Hemoglobin Glycation Index and NAFLD in Chinese Nondiabetic Individuals. Can J Gastroenterol Hepatol 2019;2019:8748459. [PMID: 31929982 DOI: 10.1155/2019/8748459] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
347 Jones GS, Alvarez CS, Graubard BI, McGlynn KA. Agreement Between the Prevalence of Nonalcoholic Fatty Liver Disease Determined by Transient Elastography and Fatty Liver Indices. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31562-7. [PMID: 33227430 DOI: 10.1016/j.cgh.2020.11.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
348 Stine JG, Munaganuru N, Barnard A, Wang JL, Kaulback K, Argo CK, Singh S, Fowler KJ, Sirlin CB, Loomba R. Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31220-9. [PMID: 32882428 DOI: 10.1016/j.cgh.2020.08.061] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
349 Webel AR, Schexnayder J, Cioe PA, Zuñiga JA. A Review of Chronic Comorbidities in Adults Living With HIV: State of the Science. J Assoc Nurses AIDS Care 2021;32:322-46. [PMID: 33595986 DOI: 10.1097/JNC.0000000000000240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
350 Fan Y, Yan LT, Yao Z, Xiong GY. Biochanin A Regulates Cholesterol Metabolism Further Delays the Progression of Nonalcoholic Fatty Liver Disease. Diabetes Metab Syndr Obes 2021;14:3161-72. [PMID: 34276221 DOI: 10.2147/DMSO.S315471] [Reference Citation Analysis]
351 Cao W, Xu Y, Shen Y, Wang Y, Ma X, Bao Y. Serum Fibroblast Growth Factor 23 Level and Liver Fat Content in MAFLD: A Community-Based Cohort. Diabetes Metab Syndr Obes 2021;14:4135-43. [PMID: 34616166 DOI: 10.2147/DMSO.S328206] [Reference Citation Analysis]
352 Martínez-Escudé A, Pera G, Costa-Garrido A, Rodríguez L, Arteaga I, Expósito-Martínez C, Torán-Monserrat P, Caballería L. TSH Levels as an Independent Risk Factor for NAFLD and Liver Fibrosis in the General Population. J Clin Med 2021;10:2907. [PMID: 34209831 DOI: 10.3390/jcm10132907] [Reference Citation Analysis]
353 Dabravolski SA, Bezsonov EE, Baig MS, Popkova TV, Nedosugova LV, Starodubova AV, Orekhov AN. Mitochondrial Mutations and Genetic Factors Determining NAFLD Risk. Int J Mol Sci 2021;22:4459. [PMID: 33923295 DOI: 10.3390/ijms22094459] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
354 Abenavoli L, Boccuto L, Federico A, Dallio M, Loguercio C, Di Renzo L, De Lorenzo A. Diet and Non-Alcoholic Fatty Liver Disease: The Mediterranean Way. Int J Environ Res Public Health. 2019;16. [PMID: 31438482 DOI: 10.3390/ijerph16173011] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 13.0] [Reference Citation Analysis]
355 Geier A, Tiniakos D, Denk H, Trauner M. From the origin of NASH to the future of metabolic fatty liver disease. Gut 2021:gutjnl-2020-323202. [PMID: 33632710 DOI: 10.1136/gutjnl-2020-323202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
356 Xia Y, Wu Q, Dai H, Lv J, Liu Y, Sun H, Jiang Y, Chang Q, Niu K, Zhao Y. Associations of Nutritional, Lifestyle, and Metabolic Factors With Non-alcoholic Fatty Liver Disease: An Umbrella Review With More Than 380,000 Participants. Front Nutr 2021;8:642509. [PMID: 34604270 DOI: 10.3389/fnut.2021.642509] [Reference Citation Analysis]
357 Yang Q, Chen X, Zhang Y, Hu S, Hu F, Huang Y, Ma T, Hu H, Tian H, Tian S, Ji YX, She ZG, Zhang P, Zhang XJ, Hu Y, Yang H, Yuan Y, Li H. The E3 Ubiquitin Ligase Ring Finger Protein 5 Ameliorates NASH Through Ubiquitin-Mediated Degradation of 3-Hydroxy-3-Methylglutaryl CoA Reductase Degradation Protein 1. Hepatology 2021. [PMID: 34272738 DOI: 10.1002/hep.32061] [Reference Citation Analysis]
358 Han H, Guo Y, Li X, Shi D, Xue T, Wang L, Li Y, Zheng M. Plant Sterol Ester of α-Linolenic Acid Attenuates Nonalcoholic Fatty Liver Disease by Rescuing the Adaption to Endoplasmic Reticulum Stress and Enhancing Mitochondrial Biogenesis. Oxid Med Cell Longev 2019;2019:8294141. [PMID: 33273997 DOI: 10.1155/2019/8294141] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
359 Han MAT, Yu Q, Tafesh Z, Pyrsopoulos N. Diversity in NAFLD: A Review of Manifestations of Nonalcoholic Fatty Liver Disease in Different Ethnicities Globally. J Clin Transl Hepatol 2021;9:71-80. [PMID: 33604257 DOI: 10.14218/JCTH.2020.00082] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
360 Zhou Q, Wang Y, Wang J, Liu Y, Qi D, Yao W, Jiang H, Li T, Huang K, Zhang W, Huo X. Prevalence and risk factor analysis for the nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Medicine (Baltimore) 2021;100:e24940. [PMID: 33725855 DOI: 10.1097/MD.0000000000024940] [Reference Citation Analysis]
361 Cernea S, Raz I. NAFLD in type 2 diabetes mellitus: Still many challenging questions. Diabetes Metab Res Rev 2021;37. [DOI: 10.1002/dmrr.3386] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
362 Wei S, Yu X. Efficacy of resveratrol supplementation on liver enzymes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. Complement Ther Med 2021;57:102635. [PMID: 33271299 DOI: 10.1016/j.ctim.2020.102635] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
363 Bravo M, Raurell I, Barberá A, Hide D, Gil M, Estrella F, Salcedo MT, Augustin S, Genescà J, Martell M. Synergic effect of atorvastatin and ambrisentan on sinusoidal and hemodynamic alterations in a rat model of NASH. Dis Model Mech 2021;14:dmm048884. [PMID: 34014280 DOI: 10.1242/dmm.048884] [Reference Citation Analysis]
364 Mato JM, Alonso C, Noureddin M, Lu SC. Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease. World J Gastroenterol 2019; 25(24): 3009-3020 [PMID: 31293337 DOI: 10.3748/wjg.v25.i24.3009] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 30] [Article Influence: 12.0] [Reference Citation Analysis]
365 Xiao Y, Kim M, Lazar MA. Nuclear receptors and transcriptional regulation in non-alcoholic fatty liver disease. Mol Metab 2021;50:101119. [PMID: 33220489 DOI: 10.1016/j.molmet.2020.101119] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
366 Younossi ZM, Anstee QM, Wai-Sun Wong V, Trauner M, Lawitz EJ, Harrison SA, Camargo M, Kersey K, Subramanian GM, Myers RP, Stepanova M. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. Gastroenterology 2021;160:1608-1619.e13. [PMID: 33307033 DOI: 10.1053/j.gastro.2020.12.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
367 Deng Y, Pan M, Nie H, Zheng C, Tang K, Zhang Y, Yang Q. Lipidomic Analysis of the Protective Effects of Shenling Baizhu San on Non-Alcoholic Fatty Liver Disease in Rats. Molecules 2019;24:E3943. [PMID: 31683679 DOI: 10.3390/molecules24213943] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
368 Tommasi S, Besaratinia A. DNA Hydroxymethylation at the Interface of the Environment and Nonalcoholic Fatty Liver Disease. Int J Environ Res Public Health 2019;16:E2791. [PMID: 31387232 DOI: 10.3390/ijerph16152791] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
369 Marini TJ, Oppenheimer DC, Baran TM, Rubens DJ, Toscano M, Drennan K, Garra B, Miele FR, Garra G, Noone SJ, Tamayo L, Carlotto C, Trujillo L, Waks E, Garra K, Egoavil MS, Berrospi J, Castaneda B. New Ultrasound Telediagnostic System for Low-Resource Areas: Pilot Results From Peru. J Ultrasound Med 2021;40:583-95. [PMID: 32798267 DOI: 10.1002/jum.15420] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
370 Fukuda A, Sasao M, Asakawa E, Narita S, Hisano M, Suruga K, Ichimura M, Tsuneyama K, Tanaka K, Omagari K. Dietary fat, cholesterol, and cholic acid affect the histopathologic severity of nonalcoholic steatohepatitis in Sprague-Dawley rats. Pathology - Research and Practice 2019;215:152599. [DOI: 10.1016/j.prp.2019.152599] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
371 Baffy G, Bosch J. Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: Is it real and how to measure it? J Hepatol 2021:S0168-8278(21)02090-0. [PMID: 34606912 DOI: 10.1016/j.jhep.2021.09.029] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
372 Groeneveld DJ, Poole LG, Luyendyk JP. Targeting von Willebrand factor in liver diseases: A novel therapeutic strategy? J Thromb Haemost 2021;19:1390-408. [PMID: 33774926 DOI: 10.1111/jth.15312] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
373 Mooli RGR, Rodriguez J, Takahashi S, Solanki S, Gonzalez FJ, Ramakrishnan SK, Shah YM. Hypoxia via ERK Signaling Inhibits Hepatic PPARα to Promote Fatty Liver. Cell Mol Gastroenterol Hepatol 2021;12:585-97. [PMID: 33798787 DOI: 10.1016/j.jcmgh.2021.03.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
374 Colognesi M, Gabbia D, De Martin S. Depression and Cognitive Impairment-Extrahepatic Manifestations of NAFLD and NASH. Biomedicines 2020;8:E229. [PMID: 32708059 DOI: 10.3390/biomedicines8070229] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
375 Lin CY, Adhikary P, Cheng K. Cellular protein markers, therapeutics, and drug delivery strategies in the treatment of diabetes-associated liver fibrosis. Adv Drug Deliv Rev 2021;174:127-39. [PMID: 33857552 DOI: 10.1016/j.addr.2021.04.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
376 Wilson SR, Burns PN, Kono Y. Contrast-Enhanced Ultrasound of Focal Liver Masses: A Success Story. Ultrasound Med Biol 2020;46:1059-70. [PMID: 32059917 DOI: 10.1016/j.ultrasmedbio.2019.12.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
377 Eskelinen S, Suvisaari JVJ, Suvisaari JM. Physical health examination in outpatients with schizophrenia: the cost effectiveness of laboratory screening tests. Ann Gen Psychiatry 2020;19:70. [PMID: 33308252 DOI: 10.1186/s12991-020-00321-3] [Reference Citation Analysis]
378 Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Targher G. Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials. Metabolites 2021;11:73. [PMID: 33513761 DOI: 10.3390/metabo11020073] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
379 Nachit M, De Rudder M, Thissen JP, Schakman O, Bouzin C, Horsmans Y, Vande Velde G, Leclercq IA. Myosteatosis rather than sarcopenia associates with non-alcoholic steatohepatitis in non-alcoholic fatty liver disease preclinical models. J Cachexia Sarcopenia Muscle 2021;12:144-58. [PMID: 33244884 DOI: 10.1002/jcsm.12646] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
380 Zhang JZ, Cai JJ, Yu Y, She ZG, Li H. Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis. Gene Expr 2019;19:187-98. [PMID: 31010457 DOI: 10.3727/105221619X15553433838609] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
381 Tavaglione F, Kono N, Romeo S. Understanding the underlying molecular pathways by which Mboat7/Lpiat1 depletion induces hepatic steatosis. J Lipid Res 2021;62:100047. [PMID: 33582144 DOI: 10.1016/j.jlr.2021.100047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
382 Li L, Xia Y, Ji X, Wang H, Zhang Z, Lu P, Ding Q, Wang D, Liu M. MIG/CXCL9 exacerbates the progression of metabolic-associated fatty liver disease by disrupting Treg/Th17 balance. Exp Cell Res 2021;407:112801. [PMID: 34461107 DOI: 10.1016/j.yexcr.2021.112801] [Reference Citation Analysis]
383 Xia Y, Wang X, Zhang S, Zhang Q, Liu L, Meng G, Wu H, Bao X, Gu Y, Sun S, Wang X, Zhou M, Jia Q, Song K, Wu Q, Niu K, Zhao Y. Daily tea drinking is not associated with newly diagnosed non-alcoholic fatty liver disease in Chinese adults: the Tianjin chronic low-grade systemic inflammation and health cohort study. Nutr J 2019;18:71. [PMID: 31711498 DOI: 10.1186/s12937-019-0502-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
384 Chang Y, He J, Xiang X, Li H. LUM is the hub gene of advanced fibrosis in nonalcoholic fatty liver disease patients. Clin Res Hepatol Gastroenterol 2021;45:101435. [PMID: 32386798 DOI: 10.1016/j.clinre.2020.04.006] [Reference Citation Analysis]
385 Samji NS, Heda R, Kovalic AJ, Satapathy SK. Similarities and Differences Between Nonalcoholic Steatohepatitis and Other Causes of Cirrhosis. Gastroenterology Clinics of North America 2020;49:151-64. [DOI: 10.1016/j.gtc.2019.09.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
386 Hydes T, Buchanan R, Kennedy OJ, Fraser S, Parkes J, Roderick P. Systematic review of the impact of non-alcoholic fatty liver disease on mortality and adverse clinical outcomes for individuals with chronic kidney disease. BMJ Open 2020;10:e040970. [PMID: 32988952 DOI: 10.1136/bmjopen-2020-040970] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
387 Xu J, Guo Y, Huang X, Ma X, Li P, Wang Y, Wang X, Yuan L. Effects of DHA dietary intervention on hepatic lipid metabolism in apolipoprotein E-deficient and C57BL/6J wild-type mice. Biomed Pharmacother 2021;144:112329. [PMID: 34653759 DOI: 10.1016/j.biopha.2021.112329] [Reference Citation Analysis]
388 Stender S, Romeo S. HSD17B13 as a promising therapeutic target against chronic liver disease. Liver Int 2020;40:756-7. [PMID: 32255570 DOI: 10.1111/liv.14411] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
389 Molina-Molina E, Shanmugam H, Di Ciaula A, Grattagliano I, Di Palo DM, Palmieri VO, Portincasa P. (13C)-Methacetin breath test provides evidence of subclinical liver dysfunction linked to fat storage but not lifestyle. JHEP Rep 2021;3:100203. [PMID: 33490935 DOI: 10.1016/j.jhepr.2020.100203] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
390 Paik JM, Deshpande R, Golabi P, Younossi I, Henry L, Younossi ZM. The impact of modifiable risk factors on the long-term outcomes of non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2020;51:291-304. [DOI: 10.1111/apt.15580] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
391 Jiang H, Qian Y, Shen Z, Liu Y, He Y, Gao R, Shen M, Chen S, Fu Q, Yang T. Circulating microRNA‑135a‑3p in serum extracellular vesicles as a potential biological marker of non‑alcoholic fatty liver disease. Mol Med Rep 2021;24:498. [PMID: 33955511 DOI: 10.3892/mmr.2021.12137] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
392 Zeng X, Zhu M, Liu X, Chen X, Yuan Y, Li L, Liu J, Lu Y, Cheng J, Chen Y. Oleic acid ameliorates palmitic acid induced hepatocellular lipotoxicity by inhibition of ER stress and pyroptosis. Nutr Metab (Lond) 2020;17:11. [PMID: 32021639 DOI: 10.1186/s12986-020-0434-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
393 Shaheen M, Schrode KM, Pan D, Kermah D, Puri V, Zarrinpar A, Elisha D, Najjar SM, Friedman TC. Sex-Specific Differences in the Association Between Race/Ethnicity and NAFLD Among US Population. Front Med (Lausanne) 2021;8:795421. [PMID: 34926533 DOI: 10.3389/fmed.2021.795421] [Reference Citation Analysis]
394 Ahn JH, Yu JS, Park KS, Kang SH, Huh JH, Chang JS, Lee JH, Kim MY, Nickel MD, Kannengiesser S, Kim JY, Koh SB. Effect of hepatic steatosis on native T1 mapping of 3T magnetic resonance imaging in the assessment of T1 values for patients with non-alcoholic fatty liver disease. Magn Reson Imaging 2021;80:1-8. [PMID: 33798658 DOI: 10.1016/j.mri.2021.03.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
395 Sun DQ, Zheng KI, Xu G, Ma HL, Zhang HY, Pan XY, Zhu PW, Wang XD, Targher G, Byrne CD, Chen YP, Yuan WJ, Zheng MH. PNPLA3 rs738409 is associated with renal glomerular and tubular injury in NAFLD patients with persistently normal ALT levels. Liver Int. 2020;40:107-119. [PMID: 31519069 DOI: 10.1111/liv.14251] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 10.3] [Reference Citation Analysis]
396 Ma P, Huang R, Jiang J, Ding Y, Li T, Ou Y. Potential use of C-phycocyanin in non-alcoholic fatty liver disease. Biochem Biophys Res Commun 2020;526:906-12. [PMID: 32279997 DOI: 10.1016/j.bbrc.2020.04.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
397 Kemp W, Clayton-Chubb D, Majeed A, Glenister KM, Magliano DJ, Lubel J, Bourke L, Simmons D, Roberts SK. Impact of renaming NAFLD to MAFLD in an Australian regional cohort: Results from a prospective population-based study. J Gastroenterol Hepatol 2021. [PMID: 34693553 DOI: 10.1111/jgh.15723] [Reference Citation Analysis]
398 Buzás GM. Helicobacter pylori and non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol 2020;66:267-79. [PMID: 32724031 DOI: 10.23736/S1121-421X.20.02671-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
399 Li S, Xu Y, Guo W, Chen F, Zhang C, Tan HY, Wang N, Feng Y. The Impacts of Herbal Medicines and Natural Products on Regulating the Hepatic Lipid Metabolism. Front Pharmacol 2020;11:351. [PMID: 32265720 DOI: 10.3389/fphar.2020.00351] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
400 Lupsor-Platon M, Serban T, Silion AI, Tirpe GR, Tirpe A, Florea M. Performance of Ultrasound Techniques and the Potential of Artificial Intelligence in the Evaluation of Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease. Cancers (Basel) 2021;13:790. [PMID: 33672827 DOI: 10.3390/cancers13040790] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
401 Li R, Toan S, Zhou H. Role of mitochondrial quality control in the pathogenesis of nonalcoholic fatty liver disease. Aging (Albany NY) 2020;12:6467-85. [PMID: 32213662 DOI: 10.18632/aging.102972] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
402 Anand A, Elhence A, Vaishnav M, Singh AA, Rajput MS, Banyal V, Jindal V, Pathak P, Kumar P, Nayak B, Yadav R, Das P, Garg H, Agarwal L, Aggarwal S, Kumar R, Shalimar. FibroScan-aspartate aminotransferase score in an Asian cohort of non-alcoholic fatty liver disease and its utility in predicting histological resolution with bariatric surgery. J Gastroenterol Hepatol 2021;36:1309-16. [PMID: 33232525 DOI: 10.1111/jgh.15358] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
403 Abenavoli L, Larussa T, Corea A, Procopio AC, Boccuto L, Dallio M, Federico A, Luzza F. Dietary Polyphenols and Non-Alcoholic Fatty Liver Disease. Nutrients 2021;13:494. [PMID: 33546130 DOI: 10.3390/nu13020494] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
404 Tang Z, Pham M, Hao Y, Wang F, Patel D, Jean-Baptiste L, Fan L, Wang W, Wang Y, Cheng F. Sex, Age, and BMI Modulate the Association of Physical Examinations and Blood Biochemistry Parameters and NAFLD: A Retrospective Study on 1994 Cases Observed at Shuguang Hospital, China. Biomed Res Int 2019;2019:1246518. [PMID: 31341886 DOI: 10.1155/2019/1246518] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
405 Li Y, Zhang T, Liu Q, Zhang J, Li R, Pu S, Wu T, Ma L, He J. Mixed micelles loaded with the 5-benzylidenethiazolidine-2,4-dione derivative SKLB023 for efficient treatment of non-alcoholic steatohepatitis. Int J Nanomedicine 2019;14:3943-53. [PMID: 31239664 DOI: 10.2147/IJN.S202821] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
406 Sangineto M, Villani R, Cavallone F, Romano A, Loizzi D, Serviddio G. Lipid Metabolism in Development and Progression of Hepatocellular Carcinoma.Cancers (Basel). 2020;12. [PMID: 32486341 DOI: 10.3390/cancers12061419] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
407 Zheng Y, Fang D, Huang C, Zhao L, Gan L, Chen Y, Liu F. Gentiana scabra Restrains Hepatic Pro-Inflammatory Macrophages to Ameliorate Non-Alcoholic Fatty Liver Disease. Front Pharmacol 2022;12:816032. [DOI: 10.3389/fphar.2021.816032] [Reference Citation Analysis]
408 Wang ZH, Zheng KI, Wang XD, Qiao J, Li YY, Zhang L, Zheng MH, Wu J. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00115-6. [PMID: 34256994 DOI: 10.1016/j.hbpd.2021.05.008] [Reference Citation Analysis]
409 Ratziu V, Rinella M, Beuers U, Loomba R, Anstee QM, Harrison S, Francque S, Sanyal A, Newsome PN, Younossi Z. The times they are a-changin' (for NAFLD as well). J Hepatol 2020;73:1307-9. [PMID: 32890593 DOI: 10.1016/j.jhep.2020.08.028] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
410 Hu W, Li M, Sun W, Li Q, Xi H, Qiu Y, Wang R, Ding Q, Wang Z, Yu Y, Lei H, Mao Y, Zhu YZ. Hirsutine ameliorates hepatic and cardiac insulin resistance in high-fat diet-induced diabetic mice and in vitro models. Pharmacol Res 2021;:105917. [PMID: 34597809 DOI: 10.1016/j.phrs.2021.105917] [Reference Citation Analysis]
411 Chan WL, Lin CC, Wei JC. Pulmonary hypertension is associated with an increased incidence of NAFLD. J Intern Med 2022. [PMID: 34984757 DOI: 10.1111/joim.13415] [Reference Citation Analysis]
412 Hirose S, Matsumoto K, Tatemichi M, Tsuruya K, Anzai K, Arase Y, Shiraishi K, Suzuki M, Ieda S, Kagawa T. Nineteen-year prognosis in Japanese patients with biopsy-proven nonalcoholic fatty liver disease: Lean versus overweight patients. PLoS One 2020;15:e0241770. [PMID: 33186403 DOI: 10.1371/journal.pone.0241770] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
413 Tutunchi H, Saghafi-Asl M, Asghari-Jafarabadi M, Ostadrahimi A. The relationship between severity of liver steatosis and metabolic parameters in a sample of Iranian adults. BMC Res Notes 2020;13:218. [PMID: 32299490 DOI: 10.1186/s13104-020-05059-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
414 Reis SS, Callejas GH, Marques RA, Gestic MA, Utrini MP, Chaim FDM, Ramos AC, Chaim EA, Cazzo E. Correlation Between Anthropometric Measurements and Non-alcoholic Fatty Liver Disease in Individuals With Obesity Undergoing Bariatric Surgery: Cross-Sectional Study. Obes Surg 2021;31:3675-85. [PMID: 33982243 DOI: 10.1007/s11695-021-05470-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
415 Jiang G, Ramachandraiah K, Murtaza MA, Wang L, Li S, Ameer K. Synergistic effects of black ginseng and aged garlic extracts for the amelioration of nonalcoholic fatty liver disease (NAFLD) in mice. Food Sci Nutr 2021;9:3091-9. [PMID: 34136174 DOI: 10.1002/fsn3.2267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
416 Ma Y, Sun K, Cao J, Qin X, Shi J, Li H, Zhang J, Zhang T. Acupuncture combined with Chinese herbal medicine on non-alcoholic fatty liver disease: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e28083. [PMID: 34941049 DOI: 10.1097/MD.0000000000028083] [Reference Citation Analysis]
417 Wu Y, Yang Y, Li F, Zou J, Wang YH, Xu MX, Wang YL, Li RX, Sun YT, Lu S, Zhang YY, Sun XD. Icaritin Attenuates Lipid Accumulation by Increasing Energy Expenditure and Autophagy Regulated by Phosphorylating AMPK. J Clin Transl Hepatol 2021;9:373-83. [PMID: 34221923 DOI: 10.14218/JCTH.2021.00050] [Reference Citation Analysis]
418 Zaky S, Alboraie M, El Badry M, Metwally MA, Abdelaziz A, Fouad Y, Abd-Elsalam S, Mahmoud A, Shiha G, Baki AA, El Kassas M, Esmat G. Management of liver disease patients in different clinical situations during COVID-19 pandemic. Egypt Liver J 2021;11:21. [PMID: 34777868 DOI: 10.1186/s43066-021-00091-x] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
419 Alemany-Pagès M, Tavares R, Varela Amaral S, Barros-Viegas AT, Oliveira PJ, Ramalho-Santos J, Azul AM. Publicly stressing the role of mitochondria in NAFLD with(in) a sports event. Eur J Clin Invest 2020;50:e13234. [PMID: 32291744 DOI: 10.1111/eci.13234] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
420 Kimura M, Mikami K, Endo T, Matsuzaka M, Sawada N, Igarashi G, Iino C, Hasegawa T, Sawada K, Ando M, Tokuda I, Suganuma H, Matsumoto M, Nakaji S, Fukuda S. Association between serum β-carotene-to-retinol ratio and severity of hepatic steatosis in non-alcoholic fatty liver disease in Japan: A cross-sectional study. Nutrition 2020;79-80:110984. [PMID: 32966920 DOI: 10.1016/j.nut.2020.110984] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
421 Chin J, Mori TA, Adams LA, Beilin LJ, Huang RC, Olynyk JK, Ayonrinde OT. Association between remnant lipoprotein cholesterol levels and non-alcoholic fatty liver disease in adolescents. JHEP Rep 2020;2:100150. [PMID: 32984791 DOI: 10.1016/j.jhepr.2020.100150] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
422 Guo C, Xue H, Guo T, Zhang W, Xuan WQ, Ren YT, Wang D, Chen YH, Meng YH, Gao HL, Zhao P. Recombinant human lactoferrin attenuates the progression of hepatosteatosis and hepatocellular death by regulating iron and lipid homeostasis in ob/ob mice. Food Funct 2020;11:7183-96. [PMID: 32756704 DOI: 10.1039/d0fo00910e] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
423 Singh MK, Jayarajan R, Varshney S, Upadrasta S, Singh A, Yadav R, Scaria V, Sengupta S, Shanmugam D, Shalimar, Sivasubbu S, Gandotra S, Sachidanandan C. Chronic systemic exposure to IL6 leads to deregulation of glycolysis and fat accumulation in the zebrafish liver. Biochim Biophys Acta Mol Cell Biol Lipids 2021;1866:158905. [PMID: 33582286 DOI: 10.1016/j.bbalip.2021.158905] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
424 Siafi E, Andrikou I, Konstantinidis D, Kakouri N, Iliakis P, Koskinas J, Koullias E, Thireos E, Tousoulis D, Thomopoulos C, Tsioufis C. Fatty liver index and hypertension-mediated organ damage in never-treated hypertensive patients without diabetes mellitus. J Hypertens 2021;39:2470-7. [PMID: 34738990 DOI: 10.1097/HJH.0000000000002954] [Reference Citation Analysis]
425 Hernández A, Geng Y, Sepúlveda R, Solís N, Torres J, Arab JP, Barrera F, Cabrera D, Moshage H, Arrese M. Chemical hypoxia induces pro-inflammatory signals in fat-laden hepatocytes and contributes to cellular crosstalk with Kupffer cells through extracellular vesicles. Biochim Biophys Acta Mol Basis Dis 2020;1866:165753. [PMID: 32126269 DOI: 10.1016/j.bbadis.2020.165753] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
426 Raimondo G, Saitta C, Lombardo D, Giraudi PJ, Rosso N, Ieni A, Lazzara S, Palmisano S, Bonazza D, Alibrandi A, Navarra G, Tiribelli C, Pollicino T. Occult hepatitis B virus infection predicts non-alcoholic steatohepatitis in severely obese individuals from Italy. Liver Int 2020;40:1601-9. [PMID: 32329579 DOI: 10.1111/liv.14473] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
427 Masroor M, Haque Z. HbA1C as a Biomarker of Non-alcoholic Fatty Liver Disease: Comparison with Anthropometric Parameters. J Clin Transl Hepatol 2021;9:15-21. [PMID: 33604251 DOI: 10.14218/JCTH.2019.00046] [Reference Citation Analysis]
428 Seidelin AS, Nordestgaard BG, Tybjærg-Hansen A, Stender S. Genetic Variation at PPP1R3B Increases Hepatic CT Attenuation and Interacts With Prandial Status on Plasma Glucose. J Clin Endocrinol Metab 2020;105:dgaa151. [PMID: 32219298 DOI: 10.1210/clinem/dgaa151] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
429 Liu J, Dong B, Yang L, Huang W, Tang S. Xuefu Zhuyu decoction for nonalcoholic fatty liver disease: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e25358. [PMID: 34106587 DOI: 10.1097/MD.0000000000025358] [Reference Citation Analysis]
430 Chen L, Yi C, Li W, Tseng Y, Zhang J, Liu J. Inhibition of SPATS2 Suppresses Proliferation and Invasion of Hepatocellular Carcinoma Cells through TRIM44-STAT3 Signaling Pathway. J Cancer 2021;12:89-98. [PMID: 33391405 DOI: 10.7150/jca.47526] [Reference Citation Analysis]
431 Tsutsumi T, Eslam M, Kawaguchi T, Yamamura S, Kawaguchi A, Nakano D, Koseki M, Yoshinaga S, Takahashi H, Anzai K, George J, Torimura T. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach. Hepatol Res 2021. [PMID: 34129272 DOI: 10.1111/hepr.13685] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
432 Hua X, Sun D, Zhang W, Fu J, Tong J, Sun S, Zeng F, Ouyang S, Zhang G, Wang S, Li D, Miao C, Wang P. P7C3‐A20 alleviates fatty liver by shaping gut microbiota and inducing FGF21/FGF1, via the AMP‐activated protein kinase/CREB regulated transcription coactivator 2 pathway. Br J Pharmacol 2021;178:2111-30. [DOI: 10.1111/bph.15008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
433 O'Gorman P, Monaghan A, McGrath M, Naimimohasses S, Gormley J, Norris S. Determinants of Physical Activity Engagement in Patients With Nonalcoholic Fatty Liver Disease: The Need for an Individualized Approach to Lifestyle Interventions. Phys Ther 2021;101:pzaa195. [PMID: 33104787 DOI: 10.1093/ptj/pzaa195] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
434 Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell’Obesità (SIO)., Members of the guidelines panel., Coordinator., AISF Members., SID Members., SIO Members., Metodologists. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Nutr Metab Cardiovasc Dis 2022;32:1-16. [PMID: 34924246 DOI: 10.1016/j.numecd.2021.04.028] [Reference Citation Analysis]
435 Li W, Alazawi W. Non-alcoholic fatty liver disease. Clin Med (Lond) 2020;20:509-12. [PMID: 32934047 DOI: 10.7861/clinmed.2020-0696] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
436 Tao MH, Fulda KG. Association of Magnesium Intake with Liver Fibrosis among Adults in the United States. Nutrients 2021;13:E142. [PMID: 33401667 DOI: 10.3390/nu13010142] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
437 Kouvari M, Boutari C, Chrysohoou C, Fragkopoulou E, Antonopoulou S, Tousoulis D, Pitsavos C, Panagiotakos DB, Mantzoros CS; ATTICA study Investigators. Mediterranean diet is inversely associated with steatosis and fibrosis and decreases ten-year diabetes and cardiovascular risk in NAFLD subjects: Results from the ATTICA prospective cohort study. Clin Nutr 2021;40:3314-24. [PMID: 33234342 DOI: 10.1016/j.clnu.2020.10.058] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
438 Shafiha R, Bahcivanci B, Gkoutos GV, Acharjee A. Machine Learning-Based Identification of Potentially Novel Non-Alcoholic Fatty Liver Disease Biomarkers. Biomedicines 2021;9:1636. [PMID: 34829865 DOI: 10.3390/biomedicines9111636] [Reference Citation Analysis]
439 Brodosi L, Marchignoli F, Marchesini G, Petroni ML. Considerations when prescribing pharmacotherapy for metabolic associated fatty liver disease. Expert Opin Pharmacother 2021;:1-5. [PMID: 34541981 DOI: 10.1080/14656566.2021.1980538] [Reference Citation Analysis]
440 Omagari K, Suzuta M, Taniguchi A, Kumamoto R, Koyama Y, Fukuda A, Suruga K, Ichimura-shimizu M, Tsuneyama K. A non-obese, diet-induced animal model of nonalcoholic steatohepatitis in Wistar/ST rats compared to Sprague-Dawley rats. Clinical Nutrition Experimental 2020;30:1-14. [DOI: 10.1016/j.yclnex.2020.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
441 Zhang S, Kumari S, Gu Y, Wu X, Li X, Meng G, Zhang Q, Liu L, Wu H, Wang Y, Zhang T, Wang X, Cao X, Li H, Liu Y, Wang X, Sun S, Wang X, Zhou M, Jia Q, Song K, Sun Z, Niu K. Soy Food Intake Is Inversely Associated with Newly Diagnosed Nonalcoholic Fatty Liver Disease in the TCLSIH Cohort Study. J Nutr 2020;150:3280-7. [PMID: 33097932 DOI: 10.1093/jn/nxaa297] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
442 Chen L, Liu J, Mei G, Chen H, Peng S, Zhao Y, Yao P, Tang Y. Quercetin and non-alcoholic fatty liver disease: A review based on experimental data and bioinformatic analysis. Food Chem Toxicol 2021;154:112314. [PMID: 34087406 DOI: 10.1016/j.fct.2021.112314] [Reference Citation Analysis]
443 Harrison SA, Ratziu V, Boursier J, Francque S, Bedossa P, Majd Z, Cordonnier G, Sudrik FB, Darteil R, Liebe R, Magnanensi J, Hajji Y, Brozek J, Roudot A, Staels B, Hum DW, Megnien SJ, Hosmane S, Dam N, Chaumat P, Hanf R, Anstee QM, Sanyal AJ. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol 2020;5:970-85. [PMID: 32763196 DOI: 10.1016/S2468-1253(20)30252-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
444 Paik JM, Henry L, Golabi P, Alqahtani SA, Trimble G, Younossi ZM. Presumed Nonalcoholic Fatty Liver Disease Among Medicare Beneficiaries With HIV, 2006-2016. Open Forum Infect Dis 2020;7:ofz509. [PMID: 31921938 DOI: 10.1093/ofid/ofz509] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
445 Zeng J, Yang RX, Sun C, Pan Q, Zhang RN, Chen GY, Hu Y, Fan JG. Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease. World J Gastroenterol 2020; 26(15): 1792-1804 [PMID: 32351294 DOI: 10.3748/wjg.v26.i15.1792] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
446 Ma N, Wang YK, Xu S, Ni QZ, Zheng QW, Zhu B, Cao HJ, Jiang H, Zhang FK, Yuan YM, Zhang EB, Chen TW, Xia J, Ding XF, Chen ZH, Zhang XP, Wang K, Cheng SQ, Qiu L, Li ZG, Yu YC, Wang XF, Zhou B, Li JJ, Xie D. PPDPF alleviates hepatic steatosis through inhibition of mTOR signaling. Nat Commun 2021;12:3059. [PMID: 34031390 DOI: 10.1038/s41467-021-23285-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
447 Maeda H, Ishima Y, Saruwatari J, Mizuta Y, Minayoshi Y, Ichimizu S, Yanagisawa H, Nagasaki T, Yasuda K, Oshiro S, Taura M, McConnell MJ, Oniki K, Sonoda K, Wakayama T, Kinoshita M, Shuto T, Kai H, Tanaka M, Sasaki Y, Iwakiri Y, Otagiri M, Watanabe H, Maruyama T. Nitric oxide facilitates the targeting Kupffer cells of a nano-antioxidant for the treatment of NASH. J Control Release 2021;341:457-74. [PMID: 34856227 DOI: 10.1016/j.jconrel.2021.11.039] [Reference Citation Analysis]
448 Schattenberg JM, Ekstedt M. Assessing the disease burden of non-alcoholic fatty liver disease in the real world - big data and big numbers. BMC Med 2019;17:123. [PMID: 31269936 DOI: 10.1186/s12916-019-1357-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
449 Martin K, Hatab A, Athwal VS, Jokl E, Piper Hanley K. Genetic Contribution to Non-alcoholic Fatty Liver Disease and Prognostic Implications. Curr Diab Rep 2021;21:8. [PMID: 33544287 DOI: 10.1007/s11892-021-01377-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
450 Cho EJ, Jung GC, Kwak MS, Yang JI, Yim JY, Yu SJ, Chung GE. Fatty Liver Index for Predicting Nonalcoholic Fatty Liver Disease in an Asymptomatic Korean Population. Diagnostics (Basel) 2021;11:2233. [PMID: 34943469 DOI: 10.3390/diagnostics11122233] [Reference Citation Analysis]
451 Cordoba-Chacon J. Loss of Hepatocyte-Specific PPARγ Expression Ameliorates Early Events of Steatohepatitis in Mice Fed the Methionine and Choline-Deficient Diet. PPAR Res 2020;2020:9735083. [PMID: 32411189 DOI: 10.1155/2020/9735083] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
452 Chuah K, Chan W. Editorial: increasing burden of nonalcoholic fatty liver disease-a call to action. Aliment Pharmacol Ther 2020;51:1429-30. [DOI: 10.1111/apt.15700] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
453 Tonev D, Shumbayawonda E, Tetlow LA, Herdman L, French M, Rymell S, Thomaides-Brears H, Caseiro-Alves F, Castelo-Branco M, Ferreira C, Coenraad M, Lamb H, Beer M, Kelly M, Banerjee R, Dollinger M; RADIcAL1. The Effect of Multi-Parametric Magnetic Resonance Imaging in Standard of Care for Nonalcoholic Fatty Liver Disease: Protocol for a Randomized Control Trial. JMIR Res Protoc 2020;9:e19189. [PMID: 33104014 DOI: 10.2196/19189] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
454 Hammoutene A, Rautou PE. Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease. J Hepatol. 2019;70:1278-1291. [PMID: 30797053 DOI: 10.1016/j.jhep.2019.02.012] [Cited by in Crossref: 68] [Cited by in F6Publishing: 68] [Article Influence: 22.7] [Reference Citation Analysis]
455 Fu K, Wang C, Ma C, Zhou H, Li Y. The Potential Application of Chinese Medicine in Liver Diseases: A New Opportunity. Front Pharmacol 2021;12:771459. [PMID: 34803712 DOI: 10.3389/fphar.2021.771459] [Reference Citation Analysis]
456 Xu N, Luo H, Li M, Wu J, Wu X, Chen L, Gan Y, Guan F, Li M, Su Z, Chen J, Liu Y. β-patchoulene improves lipid metabolism to alleviate non-alcoholic fatty liver disease via activating AMPK signaling pathway. Biomed Pharmacother 2021;134:111104. [PMID: 33341045 DOI: 10.1016/j.biopha.2020.111104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
457 Kim J, Lee SK, Jeong SY, Cho HJ, Park J, Kim TM, Kim S. Cargo proteins in extracellular vesicles: potential for novel therapeutics in non-alcoholic steatohepatitis. J Nanobiotechnology 2021;19:372. [PMID: 34789265 DOI: 10.1186/s12951-021-01120-y] [Reference Citation Analysis]
458 Atabaki-Pasdar N, Ohlsson M, Viñuela A, Frau F, Pomares-Millan H, Haid M, Jones AG, Thomas EL, Koivula RW, Kurbasic A, Mutie PM, Fitipaldi H, Fernandez J, Dawed AY, Giordano GN, Forgie IM, McDonald TJ, Rutters F, Cederberg H, Chabanova E, Dale M, Masi F, Thomas CE, Allin KH, Hansen TH, Heggie A, Hong MG, Elders PJM, Kennedy G, Kokkola T, Pedersen HK, Mahajan A, McEvoy D, Pattou F, Raverdy V, Häussler RS, Sharma S, Thomsen HS, Vangipurapu J, Vestergaard H, 't Hart LM, Adamski J, Musholt PB, Brage S, Brunak S, Dermitzakis E, Frost G, Hansen T, Laakso M, Pedersen O, Ridderstråle M, Ruetten H, Hattersley AT, Walker M, Beulens JWJ, Mari A, Schwenk JM, Gupta R, McCarthy MI, Pearson ER, Bell JD, Pavo I, Franks PW. Predicting and elucidating the etiology of fatty liver disease: A machine learning modeling and validation study in the IMI DIRECT cohorts. PLoS Med 2020;17:e1003149. [PMID: 32559194 DOI: 10.1371/journal.pmed.1003149] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
459 González-Arceo M, Gómez-Zorita S, Aguirre L, Portillo MP. Effect of Microalgae and Macroalgae Extracts on Non-Alcoholic Fatty Liver Disease. Nutrients 2021;13:2017. [PMID: 34208211 DOI: 10.3390/nu13062017] [Reference Citation Analysis]
460 Zhang YN, Wang QQ, Chen YS, Shen C, Xu CF. Association between Serum Uric Acid to HDL-Cholesterol Ratio and Nonalcoholic Fatty Liver Disease in Lean Chinese Adults. Int J Endocrinol 2020;2020:5953461. [PMID: 32273892 DOI: 10.1155/2020/5953461] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
461 Sengul C, Cakir C, Barutcu S, Sarikaya R. The prevalence and correlates of T-wave inversion in lead III in non-obese men. J Electrocardiol 2020;61:66-70. [PMID: 32554158 DOI: 10.1016/j.jelectrocard.2020.05.008] [Reference Citation Analysis]
462 Denova-Gutiérrez E, Lara-Castor L, Hernández-Alcaraz C, Hernández-Ávila M, Aguilar-Salinas C, Kershenobich D, Barquera S. Prevalence and predictors of elevated liver enzyme levels in Mexico: The Mexican National Health and Nutrition Survey, 2016. Ann Hepatol 2021;:100562. [PMID: 34653686 DOI: 10.1016/j.aohep.2021.100562] [Reference Citation Analysis]
463 Tavaglione F, Targher G, Valenti L, Romeo S. Human and molecular genetics shed lights on fatty liver disease and diabetes conundrum. Endocrinol Diabetes Metab 2020;3:e00179. [PMID: 33102799 DOI: 10.1002/edm2.179] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
464 Meringer H, Shibolet O, Deutsch L. Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm? World J Gastroenterol 2019; 25(29): 3929-3940 [PMID: 31413528 DOI: 10.3748/wjg.v25.i29.3929] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
465 Li J, Deng X, Bai T, Wang S, Jiang Q, Xu K. Resolvin D1 mitigates non-alcoholic steatohepatitis by suppressing the TLR4-MyD88-mediated NF-κB and MAPK pathways and activating the Nrf2 pathway in mice. Int Immunopharmacol 2020;88:106961. [PMID: 33182038 DOI: 10.1016/j.intimp.2020.106961] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
466 Xu L, Yin L, Qi Y, Tan X, Gao M, Peng J. 3D disorganization and rearrangement of genome provide insights into pathogenesis of NAFLD by integrated Hi-C, Nanopore, and RNA sequencing. Acta Pharm Sin B 2021;11:3150-64. [PMID: 34729306 DOI: 10.1016/j.apsb.2021.03.022] [Reference Citation Analysis]
467 Wagner KT, Randall JA, Zimmermann J, Khambaty F, Brody F. Effects of Liver Pathology on Sleeve Gastrectomy Outcomes. J Laparoendosc Adv Surg Tech A 2022. [PMID: 35021881 DOI: 10.1089/lap.2021.0799] [Reference Citation Analysis]
468 Wang XK, Peng ZG. Targeting Liver Sinusoidal Endothelial Cells: An Attractive Therapeutic Strategy to Control Inflammation in Nonalcoholic Fatty Liver Disease. Front Pharmacol 2021;12:655557. [PMID: 33935770 DOI: 10.3389/fphar.2021.655557] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
469 Lee I, Kim J, Kang H. Estimated Cardiorespiratory Fitness Attenuates the Impacts of Sarcopenia and Obesity on Non-Alcoholic Fatty Liver in Korean Adults. Int J Environ Res Public Health 2020;17:E3902. [PMID: 32486399 DOI: 10.3390/ijerph17113902] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
470 Rezaei S, Tabrizi R, Nowrouzi-Sohrabi P, Jalali M, Shabani-Borujeni M, Modaresi S, Gholamalizadeh M, Doaei S. The Effects of Vitamin D Supplementation on Anthropometric and Biochemical Indices in Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Front Pharmacol 2021;12:732496. [PMID: 34803681 DOI: 10.3389/fphar.2021.732496] [Reference Citation Analysis]
471 Goodus MT, McTigue DM. Hepatic dysfunction after spinal cord injury: A vicious cycle of central and peripheral pathology? Exp Neurol 2020;325:113160. [PMID: 31863731 DOI: 10.1016/j.expneurol.2019.113160] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
472 Liebe R, Keitel-anselmino V. Genetisches Risiko bei metabolischer Fettlebererkrankung: Gemeinsame Risikofaktoren für Fettlebererkrankung, Diabetes und Hyperlipidämie. Diabetologe 2020;16:552-9. [DOI: 10.1007/s11428-020-00647-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
473 Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Adv Cancer Res 2021;149:1-61. [PMID: 33579421 DOI: 10.1016/bs.acr.2020.10.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
474 Panyod S, Sheen LY. Beneficial effects of Chinese herbs in the treatment of fatty liver diseases. J Tradit Complement Med 2020;10:260-7. [PMID: 32670821 DOI: 10.1016/j.jtcme.2020.02.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
475 Ma Q, Yang F, Ma B, Jing W, Liu J, Guo M, Li J, Wang Z, Liu M. Prevalence of nonalcoholic fatty liver disease in mental disorder inpatients in China: an observational study. Hepatol Int 2021;15:127-36. [PMID: 33512644 DOI: 10.1007/s12072-020-10132-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
476 Lang AL, Goldsmith WT, Schnegelberger RD, Arteel GE, Beier JI. Vinyl Chloride and High-Fat Diet as a Model of Environment and Obesity Interaction. J Vis Exp 2020. [PMID: 31984951 DOI: 10.3791/60351] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
477 Han JH, Park MH, Myung CS. Garcinia cambogia Ameliorates Non-Alcoholic Fatty Liver Disease by Inhibiting Oxidative Stress-Mediated Steatosis and Apoptosis through NRF2-ARE Activation. Antioxidants (Basel) 2021;10:1226. [PMID: 34439474 DOI: 10.3390/antiox10081226] [Reference Citation Analysis]
478 Niriella MA, Kasturiratne A, Beddage TU, Withanage SA, Goonatilleke DC, Abeysinghe CP, De Mel RT, Balapitiya TL, De Silva ST, Dassanayake AS, De Silva AP, Pathmeswaran A, Wickramasinghe AR, Kato N, Silva HJ. Metabolic syndrome, but not non‐alcoholic fatty liver disease, increases 10‐year mortality: A prospective, community‐cohort study. Liver Int 2019;40:101-6. [DOI: 10.1111/liv.14237] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
479 Golabi P, Fukui N, Paik J, Sayiner M, Mishra A, Younossi ZM. Mortality Risk Detected by Atherosclerotic Cardiovascular Disease Score in Patients With Nonalcoholic Fatty Liver Disease. Hepatol Commun 2019;3:1050-60. [PMID: 31388626 DOI: 10.1002/hep4.1387] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
480 Targher G, Mantovani A, Byrne CD, Wang XB, Yan HD, Sun QF, Pan KH, Zheng KI, Chen YP, Eslam M, George J, Zheng MH. Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut. 2020;69:1545-1547. [PMID: 32414813 DOI: 10.1136/gutjnl-2020-321611] [Cited by in Crossref: 54] [Cited by in F6Publishing: 60] [Article Influence: 27.0] [Reference Citation Analysis]
481 Mantovani A, Petracca G, Csermely A, Beatrice G, Targher G. Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. Metabolites 2020;11:22. [PMID: 33396949 DOI: 10.3390/metabo11010022] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
482 Chimoriya R, Piya MK, Simmons D, Ahlenstiel G, Ho V. The Use of Two-Dimensional Shear Wave Elastography in People with Obesity for the Assessment of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. J Clin Med 2020;10:E95. [PMID: 33383965 DOI: 10.3390/jcm10010095] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
483 Abenavoli L, Milanović M, Milić N, Luzza F, Giuffrè AM. Olive oil antioxidants and non-alcoholic fatty liver disease. Expert Review of Gastroenterology & Hepatology 2019;13:739-49. [DOI: 10.1080/17474124.2019.1634544] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
484 Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell’Obesità (SIO). Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Eat Weight Disord 2021. [PMID: 34914079 DOI: 10.1007/s40519-021-01287-1] [Reference Citation Analysis]
485 Zhang E, Yin S, Zhao S, Zhao C, Yan M, Fan L, Hu H. Protective effects of glycycoumarin on liver diseases. Phytother Res 2020;34:1191-7. [PMID: 31840883 DOI: 10.1002/ptr.6598] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
486 Holzner LMW, Murray AJ. Hypoxia-Inducible Factors as Key Players in the Pathogenesis of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis. Front Med (Lausanne) 2021;8:753268. [PMID: 34692739 DOI: 10.3389/fmed.2021.753268] [Reference Citation Analysis]
487 Chen MM, Cai JJ, Yu Y, She ZG, Li H. Current and Emerging Approaches for Nonalcoholic Steatohepatitis Treatment. Gene Expr 2019;19:175-85. [PMID: 30940296 DOI: 10.3727/105221619X15536120524171] [Cited by in Crossref: 6] [Article Influence: 2.0] [Reference Citation Analysis]
488 Heo JH, Lee SR, Jo SL, Ko JW, Kwon HJ, Hong EJ. Hepatic LKB1 Reduces the Progression of Non-Alcoholic Fatty Liver Disease via Genomic Androgen Receptor Signaling. Int J Mol Sci 2021;22:7904. [PMID: 34360667 DOI: 10.3390/ijms22157904] [Reference Citation Analysis]
489 Di Costanzo A, Pacifico L, D'Erasmo L, Polito L, Martino MD, Perla FM, Iezzi L, Chiesa C, Arca M. Nonalcoholic Fatty Liver Disease (NAFLD), But not Its Susceptibility Gene Variants, Influences the Decrease of Kidney Function in Overweight/Obese Children. Int J Mol Sci 2019;20:E4444. [PMID: 31505904 DOI: 10.3390/ijms20184444] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
490 Lee C, Kim M, Han J, Yoon M, Jung Y. Mesenchymal Stem Cells Influence Activation of Hepatic Stellate Cells, and Constitute a Promising Therapy for Liver Fibrosis. Biomedicines 2021;9:1598. [PMID: 34829827 DOI: 10.3390/biomedicines9111598] [Reference Citation Analysis]
491 Luo Y, Yang P, Li Z, Luo Y, Shen J, Li R, Zheng H, Liang Y, Xia N. Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways. Drug Des Devel Ther 2019;13:4065-74. [PMID: 31819375 DOI: 10.2147/DDDT.S224688] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
492 Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Olveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal AJ; REGENERATE Study Investigators. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394:2184-2196. [PMID: 31813633 DOI: 10.1016/s0140-6736(19)33041-7] [Cited by in Crossref: 296] [Cited by in F6Publishing: 151] [Article Influence: 98.7] [Reference Citation Analysis]
493 Srinivas AN, Suresh D, Santhekadur PK, Suvarna D, Kumar DP. Extracellular Vesicles as Inflammatory Drivers in NAFLD. Front Immunol 2020;11:627424. [PMID: 33603757 DOI: 10.3389/fimmu.2020.627424] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
494 Adrian T, Sørensen IMH, Knop FK, Bro S, Ballegaard ELF, Nordestgaard BG, Fuchs A, Kofoed KF, Kühl JT, Sigvardsen PE, Hornum M, Feldt-Rasmussen B. Prevalence of non-alcoholic fatty liver disease in patients with chronic kidney disease: a case-control study. Nephrol Dial Transplant 2021:gfab266. [PMID: 34505899 DOI: 10.1093/ndt/gfab266] [Reference Citation Analysis]
495 Asimakopoulou A, Engel KM, Gassler N, Bracht T, Sitek B, Buhl EM, Kalampoka S, Pinoé-Schmidt M, van Helden J, Schiller J, Weiskirchen R. Deletion of Perilipin 5 Protects Against Hepatic Injury in Nonalcoholic Fatty Liver Disease via Missing Inflammasome Activation. Cells 2020;9:E1346. [PMID: 32481590 DOI: 10.3390/cells9061346] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
496 Dilimulati D, Cai M, Lin Z, Zhang Y, Du L, Zhou D, Zhu J, Su L, Wang Y, Zhang M, Qu S. Correlation Between Sex Hormones and Non-alcoholic Fatty Liver Disease Before and After Laparoscopic Sleeve Gastrectomy. Obes Surg 2021;31:4901-10. [PMID: 34453689 DOI: 10.1007/s11695-021-05663-9] [Reference Citation Analysis]
497 Yang FC, Xu F, Wang TN, Chen GX. Roles of vitamin A in the regulation of fatty acid synthesis. World J Clin Cases 2021; 9(18): 4506-4519 [PMID: 34222419 DOI: 10.12998/wjcc.v9.i18.4506] [Reference Citation Analysis]
498 Maltais M, Brisson D, Gaudet D. Non-Alcoholic Fatty Liver in Patients with Chylomicronemia. J Clin Med 2021;10:669. [PMID: 33572376 DOI: 10.3390/jcm10040669] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
499 Naeini F, Namkhah Z, Tutunchi H, Rezayat SM, Mansouri S, Jazayeri-Tehrani SA, Yaseri M, Hosseinzadeh-Attar MJ. Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial. Trials 2021;22:801. [PMID: 34774104 DOI: 10.1186/s13063-021-05784-7] [Reference Citation Analysis]
500 Zhang Y, Ge X, Li Y, Zhang B, Wang P, Hao M, Gao P, Zhao Y, Sun T, Lu S, Ma W. TWIST2 and the PPAR signaling pathway are important in the progression of nonalcoholic steatohepatitis. Lipids Health Dis 2021;20:39. [PMID: 33879188 DOI: 10.1186/s12944-021-01458-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
501 Del Prato S, Gallwitz B, Holst JJ, Meier JJ. The incretin/glucagon system as a target for pharmacotherapy of obesity. Obes Rev 2021. [PMID: 34713962 DOI: 10.1111/obr.13372] [Reference Citation Analysis]
502 Zhou YJ, Gao F, Liu WY, Wong GL, Mahadeva S, Raihan Nik Mustapha N, Wang XD, Chan WK, Wong VW, Zheng MH. Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2021;54:470-80. [PMID: 34152626 DOI: 10.1111/apt.16487] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
503 Pellicori P, Vaduganathan M, Ferreira JP, Zannad F, Sanyal AJ. Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: Implications for future trial design. Diabetes Metab 2021;:101281. [PMID: 34543735 DOI: 10.1016/j.diabet.2021.101281] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]